NLRP3 Modulators

Compounds of formula (I) serve as NLRP3 modulators, addressing the limitations of biologics in treating NLRP3-related diseases by offering a safer and more patient-friendly option for managing metabolic and inflammatory disorders.

JP7595642B2Active Publication Date: 2024-12-06ZOMAGEN BIOSCIENCES LTD
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2022502902
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-07-17
Filing Date
2020-07-16
Publication Date
2024-12-06
Estimated Expiration
2040-07-16

Smart Images

  • Figure 0007595642000001
    Figure 0007595642000001
  • Figure 0007595642000002
    Figure 0007595642000002
  • Figure 0007595642000003
    Figure 0007595642000003
Patent Text Reader

Abstract

Described herein are NLRP3 modulators and methods of using the NLRP3 modulators for the treatment of diseases, disorders, or conditions. Also described herein are pharmaceutical compositions containing such compounds.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] cross reference This application claims the benefit of U.S. Provisional Application No. 62 / 875,409, filed July 17, 2019, which is incorporated by reference in its entirety. [Background technology]

[0002] The NOD-like receptor (NLR) family, pyrin domain-containing protein 3 (NLRP3) inflammasome, is a crucial component of innate immune responses and inflammatory processes, and its aberrant activity is pathogenic in genetic disorders such as cryopyrin-associated periodic syndromes (CAPS), and complex diseases such as multiple sclerosis, type 2 diabetes, Alzheimer's disease, and atherosclerosis. Current treatments for NLRP3-associated diseases include biologics that target IL-1. Small molecule inhibitors of NLRP3 offer an attractive alternative to these biologics, given their potential for improving safety as well as patient comfort and compliance. Summary of the Invention

[0003] In one aspect, provided herein is a compound of formula (I):

[0004] [ka] or a pharma- ceutically acceptable salt or solvate thereof, During the ceremony, X1 is O, S, N(R3), or C(NO2)(R4); X2 is -N(R5)- or -C(R5)2-; X3 is -N(R5)- or -C(R5)2-; Y1 is O, S, or N(R8); Y2 is N or C(R9); Y3 is O or N(R 10 ) and Z is N or C(R 19 ) and R1 is,

[0005] [ka] and R2 is

[0006] [ka] and R3 is -OR 14 , -CN, -NO2, or -S(=O)2R 15 and R4 is hydrogen, C1-C6 alkyl, or C1-C6 heteroalkyl; each R5 is independently selected from hydrogen, C1-C6 alkyl, and C1-C6 heteroalkyl; R6 is -OH, -C1-C6 alkyl-OH, or -NH(R 16 ) and Each R7 is C1-C6 alkyl, -C1-C6 alkyl-CO2R 18 , C1-C6 haloalkyl, and C1-C6 heteroalkyl; or R6 and R7 combine to form a 5- or 6-membered heteroaryl ring; R8 is hydrogen, C1-C6 alkyl, or C1-C6 heteroalkyl; R9 is hydrogen, halogen, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 heteroalkyl; R 10 is -OH or -O-C1-C6 alkyl; R 11 is C1-C6 alkyl, R 12 is C1-C6 alkyl, Each R 13 is independently selected from halogen, C1-C6 alkyl, C1-C6 haloalkyl, and C1-C6 heteroalkyl; R14 is hydrogen or C1-C6 alkyl, R 15 is C1-C6 alkyl, R 16 is hydrogen, C1-C6 alkyl or -C(O)-C1-C6 alkyl; R 18 is hydrogen or C1-C6 alkyl, R 19 is hydrogen, halogen, -CN, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 heteroalkyl; Each R 20 is independently selected from C1-C6 alkyl, C1-C6 haloalkyl, and C1-C6 heteroalkyl; n is 1 or 2, p is 0, 1, 2, 3, or 4; q is 0, 1, or 2; s is 1, 2, or 3; t is 1, 2, or 3; and v is 0, 1, or 2.

[0007] In some embodiments of a compound of Formula (I) or a pharma- ceutically acceptable salt or solvate thereof, R1 is

[0008] [ka] In some embodiments of the compound of formula (I) or a pharma- ceutically acceptable salt or solvate thereof, R6 is -OH. In some embodiments of the compound of formula (I) or a pharma- ceutically acceptable salt or solvate thereof, R1 is

[0009] [ka] In some embodiments of the compound of Formula (I) or a pharma- ceutically acceptable salt or solvate thereof, Y is N(R 10In some embodiments of a compound of Formula (I) or a pharma- ceutically acceptable salt or solvate thereof, R 10 is -OH. In some embodiments of a compound of formula (I) or a pharma- ceutically acceptable salt or solvate thereof, Y3 is O. In some embodiments of a compound of formula (I) or a pharma- ceutically acceptable salt or solvate thereof, Y2 is C(R9). In some embodiments of a compound of formula (I) or a pharma- ceutically acceptable salt or solvate thereof, R9 is selected from hydrogen and C1-C6 alkyl. In some embodiments of a compound of formula (I) or a pharma- ceutically acceptable salt or solvate thereof, R9 is hydrogen. In some embodiments of a compound of formula (I) or a pharma- ceutically acceptable salt or solvate thereof, Y1 is O. In some embodiments of a compound of formula (I) or a pharma- ceutically acceptable salt or solvate thereof, each R7 is independently selected from C1-C6 alkyl. In some embodiments of a compound of formula (I) or a pharma- ceutically acceptable salt or solvate thereof, each R7 is -CH3. In some embodiments of a compound of Formula (I) or a pharma- ceutically acceptable salt or solvate thereof, p is 1. In some embodiments of a compound of Formula (I) or a pharma- ceutically acceptable salt or solvate thereof, p is 2. In some embodiments of a compound of Formula (I) or a pharma- ceutically acceptable salt or solvate thereof, p is 3. In some embodiments of a compound of Formula (I) or a pharma- ceutically acceptable salt or solvate thereof, p is 0. In some embodiments of a compound of Formula (I) or a pharma- ceutically acceptable salt or solvate thereof, n is 1. In some embodiments of a compound of Formula (I) or a pharma- ceutically acceptable salt or solvate thereof, n is 2. In some embodiments of a compound of Formula (I) or a pharma- ceutically acceptable salt or solvate thereof, R1 is

[0010] [ka] In some embodiments of the compound of formula (I) or a pharma- ceutically acceptable salt or solvate thereof, R2 is

[0011] [ka] In some embodiments of a compound of Formula (I) or a pharma- ceutically acceptable salt or solvate thereof, s is 1. In some embodiments of a compound of Formula (I) or a pharma- ceutically acceptable salt or solvate thereof, t is 1. In some embodiments of a compound of Formula (I) or a pharma- ceutically acceptable salt or solvate thereof, R2 is

[0012] [ka] In some embodiments of a compound of Formula (I) or a pharma- ceutically acceptable salt or solvate thereof, each R 13 is independently selected from halogen, C1-C6 alkyl, and C1-C6 haloalkyl. In some embodiments of a compound of Formula (I) or a pharma- ceutically acceptable salt or solvate thereof, q is 1. In some embodiments of a compound of Formula (I) or a pharma- ceutically acceptable salt or solvate thereof, q is 0. In some embodiments of a compound of Formula (I) or a pharma- ceutically acceptable salt or solvate thereof, Z is C(R 19 In some embodiments of a compound of Formula (I) or a pharma- ceutically acceptable salt or solvate thereof, R 19 is hydrogen, halogen, -CN, C1-C6 alkyl, or C1-C6 haloalkyl. In some embodiments of a compound of Formula (I) or a pharma- ceutically acceptable salt or solvate thereof, R 19 In some embodiments of a compound of Formula (I) or a pharma- ceutically acceptable salt or solvate thereof, R 19In some embodiments of the compound of formula (I) or a pharma- ceutically acceptable salt or solvate thereof, R2 is

[0013] [ka] In some embodiments of a compound of formula (I) or a pharma- ceutically acceptable salt or solvate thereof, X2 is -N(R5)-. In some embodiments of a compound of formula (I) or a pharma- ceutically acceptable salt or solvate thereof, X3 is -N(R5)-. In some embodiments of a compound of formula (I) or a pharma- ceutically acceptable salt or solvate thereof, R5 is hydrogen. In some embodiments of a compound of formula (I) or a pharma- ceutically acceptable salt or solvate thereof, X3 is -CH2-. In some embodiments of a compound of formula (I) or a pharma- ceutically acceptable salt or solvate thereof, X1 is O.

[0014] In another aspect, provided herein is a pharmaceutical composition comprising a compound of formula (I) or a pharma- ceutically acceptable salt or solvate thereof, and a pharma- ceutically acceptable excipient.

[0015] In some embodiments, provided herein is a method for treating a metabolic disease in a patient in need of treatment, comprising administering to the patient a therapeutically effective amount of a compound of formula (I) or a pharma- ceutically acceptable salt or solvate thereof.In some embodiments, provided herein is a method for treating a metabolic disease in a patient in need of treatment, comprising administering to the patient a therapeutically effective amount of a compound of formula (I) or a pharma-ceutically acceptable salt or solvate thereof, wherein the metabolic disease is selected from type 2 diabetes, atherosclerosis, obesity and gout.

[0016] In some embodiments, provided herein is a method for treating liver disease in a patient in need of treatment, comprising administering to the patient a therapeutically effective amount of the compound of formula (I) or its pharmaceutically acceptable salt or solvate.In some embodiments, provided herein is a method for treating liver disease in a patient in need of treatment, comprising administering to the patient a therapeutically effective amount of the compound of formula (I) or its pharmaceutically acceptable salt or solvate, wherein said liver disease is selected from non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH), viral hepatitis and cirrhosis.

[0017] In some embodiments, provided herein is a method for treating a pulmonary disease in a patient in need of treatment, comprising administering to the patient a therapeutically effective amount of a compound of formula (I) or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, provided herein is a method for treating a pulmonary disease in a patient in need of treatment, comprising administering to the patient a therapeutically effective amount of a compound of formula (I) or a pharma- ceutically acceptable salt or solvate thereof, wherein the pulmonary disease is selected from asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis.

[0018] In some embodiments, provided herein is a method for treating a central nervous system disease in a patient in need of treatment, comprising administering to the patient a therapeutically effective amount of a compound of formula (I) or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, provided herein is a method for treating a central nervous system disease in a patient in need of treatment, comprising administering to the patient a therapeutically effective amount of a compound of formula (I) or a pharma- ceutically acceptable salt or solvate thereof, wherein the central nervous system disease is selected from Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis, and Parkinson's disease.

[0019] In some embodiments, provided herein is a method for treating an autoimmune disease in a patient in need of treatment, comprising administering to the patient a therapeutically effective amount of a compound of formula (I) or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, provided herein is a method for treating an autoimmune disease in a patient in need of treatment, comprising administering to the patient a therapeutically effective amount of a compound of formula (I) or a pharma- ceutically acceptable salt or solvate thereof, wherein the autoimmune disease is selected from rheumatoid arthritis, multiple sclerosis, psoriasis, lupus, inflammatory bowel disease, Crohn's disease, and ulcerative colitis.

[0020] In some embodiments, provided herein is a method for treating cardiovascular disease in a patient in need of treatment, comprising administering to the patient a therapeutically effective amount of a compound of formula (I) or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, provided herein is a method for treating cardiovascular disease in a patient in need of treatment, comprising administering to the patient a therapeutically effective amount of a compound of formula (I) or a pharma-ceutically acceptable salt or solvate thereof, wherein the cardiovascular disease is selected from atherosclerosis or stroke.

[0021] Incorporation by Reference All publications, patents, and patent applications cited in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0022] Detailed Description of the Invention definition In the context of this disclosure, a number of terms will be utilized.

[0023] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood to belong to the claimed subject matter. In the event that there are multiple definitions for terms herein, the definitions in this section shall prevail. All patents, patent applications, publications, and published nucleotide and amino acid sequences (e.g., sequences available in GenBank or other databases) referenced herein are incorporated by reference. When referring to a URL or other such identifier or address, it is understood that such identifiers may change and specific information on the Internet may come and go, but equivalent information may be found by searching the Internet. Reference thereto evidences the availability and public dissemination of such information.

[0024] It is to be understood that the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the claimed subject matter. In this application, the use of the singular includes the plural unless specifically stated otherwise. It should be noted that as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly indicates otherwise. In this application, the use of "or" means "and / or" unless specifically stated otherwise. Furthermore, the use of the term "including," as well as other forms such as "include," "includes," and "included," is not limiting.

[0025] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.

[0026] Definitions of standard chemical terms can be found in reference texts including, but not limited to, Carey and Sundberg, "Advanced Organic Chemistry 4th Ed." Vols. A (2000) and B (2001), Plenum Press, New York. Unless otherwise indicated, conventional methods of mass spectrometry, NMR, HPLC, protein chemistry, biochemistry, recombinant DNA techniques and pharmacology.

[0027] Unless specific definitions are provided, the nomenclature used in connection with analytical chemistry, synthetic organic chemistry, and medicinal chemistry, as well as the experimental procedures and techniques described herein, are those recognized in the art. Standard techniques can be used for chemical synthesis, chemical analysis, pharmaceutical preparation, formulation, delivery, and patient treatment. Standard techniques can be used for recombinant DNA, oligonucleotide synthesis, and tissue culture and transformation (e.g., electroporation, lipofection). Reactions and purification techniques can be performed, for example, using manufacturer's specification kits or as commonly accomplished in the art or as described herein. The aforementioned techniques and procedures can generally be performed in a conventional manner and are described in various general and more specific references cited and discussed throughout this specification.

[0028] It should be understood that the methods and compositions described herein are not limited to the specific methodologies, protocols, cell lines, constructs, and reagents described herein, as such may vary. It should also be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the methods, compounds, compositions described herein.

[0029] As used herein, C1-C x is C1-C2, C1-C3...C1-C x Includes: C1-C xrefers to the number of carbon atoms (excluding optional substituents) that make up the moiety it designates.

[0030] An "alkyl" group refers to a straight or branched chain hydrocarbon radical consisting solely of carbon and hydrogen atoms, without unsaturation. In some embodiments, an "alkyl" group may have 1-6 carbon atoms (wherever this appears herein, a numerical range such as "1-6" refers to each integer within the given range, e.g., "1-6 carbon atoms". This means that an alkyl group may consist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to 6 carbon atoms, although the current definition also covers the occurrence of the term "alkyl" where no numerical range is specified). The alkyl group of the compounds described herein may be designated as "C1-C6 alkyl" or a similar designation. By way of example only, "C1-C6 alkyl" indicates that there are 1-6 carbon atoms in the alkyl chain, i.e., the alkyl chain is selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, isopentyl, neopentyl, and hexyl. The alkyl group may be substituted or unsubstituted. Depending on the structure, an alkyl group can be a monoradical or a diradical (ie, an alkylene group).

[0031] "Alkoxy" refers to the group "-O-alkyl" where alkyl is as defined herein.

[0032] The term "alkenyl" refers to a straight or branched hydrocarbon radical group consisting solely of carbon and hydrogen atoms containing at least one carbon-carbon double bond. Non-limiting examples of alkenyl groups include -CH=CH2, -C(CH3)=CH2, -CH=CHCH3, -CH=C(CH3)2, and -C(CH3)=CHCH3. In some embodiments, an alkenyl group can have 2-6 carbons. Alkyl groups can be substituted or unsubstituted. Depending on the structure, an alkenyl group can be monoradical or diradical (i.e., an alkenylene group).

[0033] The term "alkynyl" refers to a straight or branched hydrocarbon radical group consisting solely of carbon and hydrogen atoms, containing at least one carbon-carbon triple bond. Non-limiting examples of alkynyl groups include -C≡CH, -C≡CCH3, -C≡CCH2CH3 and -C≡CCH2CH2CH3. In some embodiments, alkynyl groups can have 2-6 carbons. Alkynyl groups can be substituted or unsubstituted. Depending on the structure, alkynyl groups can be monoradical or diradical (i.e., alkynylene groups).

[0034] "Amino" refers to the group -NH2.

[0035] The term "alkylamine" or "alkylamino" refers to -N(alkyl) x H y "Dialkylamino" refers to the -N(alkyl)2 group, where alkyl is as defined herein, and x and y are selected from groups where x=1, y=1 and x=2, y=0. When x=2, the alkyl groups, together with the nitrogen to which they are attached, can optionally form a cyclic ring system. "Dialkylamino" refers to the -N(alkyl)2 group, where alkyl is as defined herein.

[0036] The term "aromatic" refers to a planar ring having a delocalized π-electron system containing 4n+2 π electrons, where n is an integer. Aromatic rings can be formed from 5, 6, 7, 8, 9, or more than 9 atoms. Aromatic compounds can be optionally substituted. The term "aromatic" includes both aryl (e.g., phenyl, naphthalenyl) and heteroaryl (e.g., pyridinyl, quinolinyl) groups.

[0037] As used herein, the term "aryl" refers to an aromatic ring in which each of the atoms forming the ring is a carbon atom. The aryl ring can be formed of 5, 6, 7, 8, 9, or more than 9 carbon atoms. The aryl group can be optionally substituted. Examples of aryl groups include, but are not limited to, phenyl and naphthalenyl. Depending on the structure, the aryl group can be monoradical or diradical (i.e., an arylene group).

[0038] "Carboxy" refers to -CO2H. In some embodiments, the carboxy moiety can be replaced with a "carboxylic acid bioisostere," which refers to a functional group or moiety that exhibits similar physical and / or chemical properties as a carboxylic acid moiety. A carboxylic acid bioisostere has similar biological properties as a carboxylic acid group. A compound having a carboxylic acid moiety can have the carboxylic acid moiety replaced with a carboxylic acid bioisostere and can have similar physical and / or biological properties when compared to the carboxylic acid-containing compound. For example, in one embodiment, the carboxylic acid bioisostere ionizes at physiological pH to approximately the same extent as a carboxylic acid group. Examples of carboxylic acid bioisosteres include, but are not limited to, the following:

[0039] [ka]

[0040] The term "cycloalkyl" refers to a monocyclic or polycyclic non-aromatic group, in which each atom forming the ring (i.e., skeletal atoms) is a carbon atom. A cycloalkyl can be saturated or partially unsaturated. A cycloalkyl can be fused to an aromatic ring (in which case the cycloalkyl is attached through a carbon atom of the non-aromatic ring). In some embodiments, cycloalkyl groups include groups having from 3 to 10 ring atoms.

[0041] The terms "heteroaryl" or, alternatively, "heteroaromatic" refer to an aryl group that contains one or more ring heteroatoms selected from nitrogen, oxygen, and sulfur. An N-containing "heteroaromatic" or "heteroaryl" moiety refers to an aromatic group in which at least one of the skeletal atoms of the ring is a nitrogen atom.

[0042] A "heterocycloalkyl" or "heteroalicyclic" group refers to a cycloalkyl group in which at least one skeletal ring atom is a heteroatom selected from nitrogen, oxygen, and sulfur. The radical can be fused with an aryl or heteroaryl. The term heteroalicyclic also includes carbohydrates of all ring forms, including but not limited to monosaccharides, disaccharides, and oligosaccharides. Unless otherwise noted, a heterocycloalkyl has 2-10 carbons in the ring. When referring to the number of carbon atoms in a heterocycloalkyl, it is understood that the number of carbon atoms in the heterocycloalkyl is not the same as the total number of atoms (including heteroatoms) that make up the heterocycloalkyl (i.e., the skeletal atoms of the heterocycloalkyl ring).

[0043] The term "halo" or, alternatively, "halogen" means fluoro, chloro, bromo and iodo.

[0044] The term "haloalkyl" refers to an alkyl group substituted with one or more halogens. The halogens can be the same or different. Non-limiting examples of haloalkyls include -CH2Cl, -CF3, -CHF2, -CH2CF3, -CF2CF3, and the like.

[0045] The terms "fluoroalkyl" and "fluoroalkoxy" include alkyl and alkoxy groups, respectively, substituted with one or more fluorine atoms. Non-limiting examples of fluoroalkyl include -CF3, -CHF2, -CH2F, -CH2CF3, -CF2CF3, -CF2CF2CF3, -CF(CH3)3, and the like. Non-limiting examples of fluoroalkoxy groups include -OCF3, -OCHF2, -OCH2F, -OCH2CF3, -OCF2CF3, -OCF2CF2CF3, -OCF(CH3)2, and the like.

[0046] The term "heteroalkyl" refers to an alkyl radical in which one or more skeletal atoms are selected from atoms other than carbon, such as oxygen, nitrogen, sulfur, phosphorus, silicon, or combinations thereof. The heteroatoms can be located at any interior position of the heteroalkyl radical. Examples include, but are not limited to, -CH2-O-CH3, -CH2-CH2-O-CH3, -CH2-NH-CH3, -CH2-CH2-NH-CH3, -CH2-N(CH3)-CH3, -CH2-CH2-NH-CH3, -CH2-CH2-N(CH3)-CH3, -CH2-CH2-NH-CH3, -CH2-CH2-N(CH3)-CH3, -CH2-S-CH2-CH3, -CH2-CH2-S(O)-CH3, -CH2-CH2-S(O)2-CH3, -CH2-NH-OCH3, -CH2-O-Si(CH3)3, -CH2-CH=N-OCH3, and -CH=CH-N(CH3)-CH3. Additionally, up to two heteroatoms may be consecutive, such as, for example, -CH2-NH-OCH3 and -CH2-O-Si(CH3)3. Excluding the number of heteroatoms, a "heteroalkyl" may have from 1 to 6 carbon atoms.

[0047] The term "bond" or "single bond" refers to a chemical bond between two atoms, or two moieties when the atoms joined by the bond are considered to be part of a larger substructure.

[0048] The term "moiety" refers to a specific segment or functional group of a molecule. A chemical moiety is often recognized as a chemical entity embedded in or appended to a molecule.

[0049] As used herein, the substituent "R" appearing by itself without a number designation refers to a substituent selected from among alkyl, haloalkyl, heteroalkyl, alkenyl, cycloalkyl, aryl, heteroaryl (bonded via a ring carbon), and heterocycloalkyl.

[0050] "Optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and the description includes instances when the event or circumstance occurs and instances when it does not occur.

[0051] The term "optionally substituted" or "substituted" means that the referenced group may be substituted with one or more further groups individually and independently selected from alkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, -OH, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfoxide, arylsulfoxide, alkylsulfone, arylsulfone, -CN, alkyne, C1-C6 alkylalkyne, halo, acyl, acyloxy, -CO2H, -CO2-alkyl, nitro, haloalkyl, fluoroalkyl, and amino, including mono- and di-substituted amino groups (e.g., -NH2, -NHR, -N(R)2), and protected derivatives thereof. By way of example, optional substituents are L s R s Each L s is independently selected from a bond, -O-, -C(=O)-, -S-, -S(=O)-, -S(=O)2-, -NH-, -NHC(O)-, -C(O)NH-, S(=O)2NH-, -NHS(=O)2, -OC(O)NH-, -NHC(O)O-, -(C1-C6 alkyl)-, or -(C2-C6 alkenyl)-; sis independently selected from H, (C1-C6 alkyl), (C3-C8 cycloalkyl), aryl, heteroaryl, heterocycloalkyl, and C1-C6 heteroalkyl. Protecting groups that may form the protective derivatives of the above substituents can be found in sources such as Greene and Wuts, above.

[0052] As used herein, the term "about" or "approximately" means within 20%, preferably within 10%, and more preferably within 5% of a given value or range.

[0053] As used herein, the term "therapeutically effective amount" refers to an amount of an NLRP3 inhibitor that is effective, when administered to a mammal in need thereof, to at least partially ameliorate or at least partially prevent a condition associated with skin aging.

[0054] As used herein, the term "expression" includes the process by which a polynucleotide is transcribed into mRNA and translated into a peptide, polypeptide, or protein.

[0055] The term "modulate" encompasses either a decrease or an increase in activity or expression, depending on the target molecule.

[0056] The term "activator" is used herein to denote any molecular species that, when locally administered, results in activation of the indicated receptor, regardless of whether the molecular species itself binds to the receptor or whether a metabolite of the molecular species binds to the receptor. Thus, an activator can be a ligand of the receptor, or it can be an activator that is metabolized to a ligand of the receptor, i.e., a metabolite that is formed in the tissue and is the actual ligand.

[0057] The term "patient" or "mammal" refers to a human, non-human primate, canine, feline, bovine, ovine, porcine, murine, or other veterinary or laboratory mammal. One of skill in the art will recognize that a treatment that reduces the severity of a condition in one species of mammal is predictive of the effectiveness of that treatment on another species of mammal.

[0058] "Pharmaceutically acceptable salts" includes both acid and base addition salts, and is intended to encompass any and all pharma- ceutically suitable salt forms of any one of the compounds described herein. Preferred pharma-ceutically acceptable salts of the compounds described herein are pharma-ceutically acceptable acid addition salts and pharma-ceutically acceptable base addition salts.

[0059] "Pharmaceutically acceptable acid addition salt" refers to salts which retain the biological effectiveness and properties of the free base and which are not biologically or otherwise undesirable, such as salts formed with inorganic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, hydroiodic acid, hydrofluoric acid, phosphoric acid, etc. Also included are salts formed with organic acids, such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxyalkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, and the like, and include, for example, acetic acid, trifluoroacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like. Thus, exemplary salts include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, sulfite, bisulfite, nitrate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, trifluoroacetate, propionate, caprylate, isobutyrate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, phthalate, benzenesulfonate, toluenesulfonate, phenylacetate, citrate, lactate, malate, tartrate, methanesulfonate, and the like. Salts of amino acids such as arginate, gluconate, and galacturonate are also contemplated (see, e.g., Berge SM et al., "Pharmaceutical Salts," Journal of Pharmaceutical Science, 66:1-19 (1997)). Acid addition salts of basic compounds are prepared by contacting the free base form with a sufficient amount of the desired acid to produce the salt.

[0060] "Pharmaceutically acceptable base addition salt" refers to a salt that retains the biological effectiveness and properties of the free acid and is not biologically or otherwise undesirable. These salts are prepared from the addition of an inorganic or organic base to the free acid. In some embodiments, pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Salts derived from inorganic bases include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts, and the like. Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, diethanolamine, 2 dimethylaminoethanol, 2 diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, N,N-dibenzylethylenediamine, chloroprocaine, hydrabamine, choline, betaine, ethylenediamine, ethylenedianiline, N-methylglucamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins, and the like. See Berge et al., supra.

[0061] As used herein, "treatment" or "treating" or "alleviating" or "ameliorating" are used interchangeably herein. These terms refer to an approach to obtain a beneficial or desired result, including but not limited to therapeutic benefit and / or preventive benefit. "Therapeutic benefit" refers to the eradication or amelioration of the underlying disease being treated. Also, therapeutic benefit is achieved by eradication or amelioration of one or more physiological symptoms associated with the underlying disease, such that improvement is observed in the patient, even though the patient still suffers from the underlying disease. For preventive benefit, the composition is administered to a patient at risk of developing a particular disease or who reports one or more physiological symptoms of the disease, even if a diagnosis of this disease has not been made.

[0062] NLRP3 Modulators NLRP3 is an intracellular signaling molecule that senses environmental and host-derived factors from many pathogens. Upon activation, NLRP3 binds to the apoptosis-associated speck-like protein, which contains a caspase activation and recruitment domain (ASC). ASC then polymerizes to form large aggregates called ASC speck.

[0063] Polymerized ASC associates with the cysteine ​​protease caspase-1 to form a complex called the inflammasome. This activates active caspase-1, which cleaves the precursor forms of the proinflammatory cytokines IL-1β and IL-18 (called pro-IL-γ and pro-IL-18, respectively), thereby activating these cytokines. Caspase-1 also mediates a form of inflammatory cell death known as pyroptosis. ASC speck aggregates can also recruit and activate caspase-8, which can process pro-IL-1β and IL-18, triggering apoptotic cell death.

[0064] Caspase-1 cleaves pro-IL-Iβ and pro-IL-18 into their active forms, which are secreted from cells. Active caspase-1 also cleaves gasdermin-D to cause pyroptosis. Caspase-1 also mediates the release of alarmin molecules such as IL-33 and high mobility group box 1 protein (HMGB1) through controlling the pyroptosis cell death pathway. Caspase-1 also cleaves intracellular IL-1R2, resulting in its degradation and allowing the release of IL-1α. In human cells, caspase-1 may also control the processing and secretion of IL-37. Many other caspase i substrates, such as components of the cytoskeleton and glycolytic pathways, may contribute to caspase I-dependent inflammation.

[0065] NLRP3-dependent ASC specks are released into the extracellular milieu where they can activate caspase-1, induce processing of caspase-1 substrates, and propagate inflammation. Active cytokines derived from NLRP3 inflammasome activation are key drivers of inflammation and interact with other cytokine pathways to shape immune responses to infection and injury. For example, IL-1β signaling induces secretion of the proinflammatory cytokines IL-6 and TNF. IL-1β and IL-18 synergize with IL-23 to induce IL-17 production by memory CD4 Th17 cells and γδ T cells in the absence of T cell receptor engagement. IL-18 and IL-12 also synergize to induce IFN-γ production from memory T cells and NK cells that drive Th1 responses.

[0066] The inherited CAPS disorders Muckle-Wells syndrome (MWS), familial cold autoinflammatory syndrome (FCAS) and neonatal-onset multisystem inflammatory disease (NOMID) are caused by gain-of-function mutations in NLRP3, thus defining it as a critical component of the inflammatory process. NLRP3 has also been implicated in the pathogenesis of many complex diseases, including metabolic diseases such as type 2 diabetes, atherosclerosis, obesity, and gout, among others.

[0067] The role of NLRP3 in diseases of the central nervous system is becoming clear, and lung diseases have also been shown to be influenced by NLRP3. In addition, NLRP3 plays a role in the development of liver disease, kidney disease, and aging. Many of these associations were defined using NLRP3 KO mice, but there are also insights into the specific activation of NLRP3 in these diseases. In type 2 diabetes (T2D), deposition of islet amyloid polypeptide in the pancreas activates NLRP3 and IL-1β signaling, leading to cell death and inflammation.

[0068] Current treatments for NLRP3-associated diseases include biologic agents that target IL-1. These are the recombinant IL-1 receptor antagonist anakinra, the neutralizing IL-1β antibody canakinumab, and the soluble decoy IL1 receptor rilonacept. These approaches have proven successful in treating CAPS, and these biologic agents have been used in clinical trials for other IL-1β-associated diseases. Small molecule inhibitors of NLRP3 offer an attractive alternative to these biologics, given the potential for improved safety (minimal risk of infection compared to biologics, and ease of withdrawal) as well as patient comfort and compliance.

[0069] The compounds of formula (I), (Ia) or (Ib) described herein are NLRP3 modulators.The compounds of formula (I), (Ia) or (Ib) described herein and compositions containing these compounds are useful for treating NLRP3-related diseases, including but not limited to type 2 diabetes, atherosclerosis, obesity and gout.

[0070] In some embodiments, provided herein is a compound of formula (I):

[0071] [ka] or a pharma- ceutically acceptable salt or solvate thereof, During the ceremony, X1 is O, S, N(R3), or C(NO2)(R4); X2 is -N(R5)- or -C(R5)2-; X3 is -N(R5)- or -C(R5)2-; Y1 is O, S, or N(R8); Y2 is N or C(R9); Y3 is O or N(R 10 ) and Z is N or C(R 19 ) and R1 is,

[0072] [ka] and R2 is

[0073] [ka] and R3 is -OR 14 , -CN, -NO2, or -S(=O)2R 15 and R4 is hydrogen, C1-C6 alkyl, or C1-C6 heteroalkyl; each R5 is independently selected from hydrogen, C1-C6 alkyl, and C1-C6 heteroalkyl; R6 is -OH, -C1-C6 alkyl-OH, or -NH(R 16 ) and Each R7 is C1-C6 alkyl, -C1-C6 alkyl-CO2R 18 , C1-C6 haloalkyl, and C1-C6 heteroalkyl, or R6 and R7 combine to form a 5- or 6-membered heteroaryl ring; R8 is hydrogen, C1-C6 alkyl, or C1-C6 heteroalkyl; R9 is hydrogen, halogen, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 heteroalkyl; R 10 is -OH or -O-C1-C6 alkyl; R 11 is C1-C6 alkyl, R 12 is C1-C6 alkyl, Each R 13 is independently selected from halogen, C1-C6 alkyl, C1-C6 haloalkyl, and C1-C6 heteroalkyl; R 14 is hydrogen or C1-C6 alkyl; R 15 is C1-C6 alkyl, R 16 is hydrogen, C1-C6 alkyl or -C(O)-C1-C6 alkyl; R 18 is hydrogen or C1-C6 alkyl; R 19 is hydrogen, halogen, -CN, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 heteroalkyl; Each R 20 is independently selected from C1-C6 alkyl, C1-C6 haloalkyl, and C1-C6 heteroalkyl; n is 1 or 2, p is 0, 1, 2, 3, or 4; q is 0, 1, or 2; s is 1, 2, or 3; t is 1, 2, or 3; and v is 0, 1, or 2.

[0074] Some embodiments are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R1 is:

[0075] [ka] Some embodiments are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R1 is:

[0076] [ka] Some embodiments are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R1 is:

[0077] [ka] Some embodiments are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R1 is:

[0078] [ka] Some embodiments are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R1 is:

[0079] [ka] Some embodiments are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R1 is:

[0080] [ka] Some embodiments are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R1 is:

[0081] [ka] Some embodiments are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R1 is:

[0082] [ka] It is.

[0083] Some embodiments are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, where R6 is -OH. Some embodiments are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, where R6 is -C1-C6 alkyl-OH. Some embodiments are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, where R6 is -NH(R 16 Some embodiments are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R6 is -NH(R 16 ) and R 16 is hydrogen. Some embodiments are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R6 is -NH(R 16 ) and R 16 is C1-C6 alkyl. Some embodiments are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R6 is -NH(R 16 ) and R 16 is -C(O)-C1-C6 alkyl.

[0084] In some embodiments, in a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, each R7 is C1-C6 alkyl, -C1-C6 alkyl-CO2R 18 , C1-C6 haloalkyl, and C1-C6 heteroalkyl. Some embodiments are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein each R7 is independently selected from C1-C6 alkyl, -C1-C6 alkyl-CO2R 18In some embodiments, each R7 is independently selected from C1-C6 alkyl, and C1-C6 haloalkyl. ... haloalkyl, and C1-C6 haloalkyl. In some embodiments, each R7 is independently selected from C1-C6 haloalkyl, and C1-C6 haloalkyl. In some embodiments, each R7 is independently selected from C1-C6 haloalkyl, and C1-C6 haloalkyl.

[0085] In some embodiments, provided herein are compounds of formula (I), or pharma- ceutically acceptable salts or solvates thereof, where p is 0, 1, 2, or 3. In some embodiments, provided herein are compounds of formula (I), or pharma- ceutically acceptable salts or solvates thereof, where p is 0. In some embodiments, provided herein are compounds of formula (I), or pharma- ceutically acceptable salts or solvates thereof, where p is 1. In some embodiments, provided herein are compounds of formula (I), or pharma- ceutically acceptable salts or solvates thereof, where p is 2. In some embodiments, provided herein are compounds of formula (I), or pharma- ceutically acceptable salts or solvates thereof, where p is 3. In some embodiments, provided herein are compounds of formula (I), or pharma- ceutically acceptable salts or solvates thereof, where p is 4.

[0086] In some embodiments, provided herein are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, where n is 1. In some embodiments, provided herein are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, where n is 2.

[0087] In some embodiments, provided herein are compounds of Formula (I), or a pharma- ceutically acceptable salt or solvate thereof, where v is 0. In some embodiments, provided herein are compounds of Formula (I), or a pharma- ceutically acceptable salt or solvate thereof, where v is 1. In some embodiments, provided herein are compounds of Formula (I), or a pharma- ceutically acceptable salt or solvate thereof, where v is 2.

[0088] In some embodiments, provided herein are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein Y is O. In some embodiments, provided herein are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein Y is N(R 10 In some embodiments, provided herein are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein Y is N(R 10 ) and R 10 In some embodiments, provided herein are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein Y is N(R 10 ) and R 10 is -O-C1-C6 alkyl.

[0089] In some embodiments, provided herein are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, where Y1 is O. In some embodiments, provided herein are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, where Y1 is S. In some embodiments, provided herein are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, where Y1 is N(R8). In some embodiments, provided herein are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, where Y1 is N(R8), where R8 is hydrogen or C1-C6 alkyl.

[0090] In some embodiments, provided herein are compounds of formula (I), or pharma- ceutically acceptable salts or solvates thereof, where Y2 is N. In some embodiments, provided herein are compounds of formula (I), or pharma- ceutically acceptable salts or solvates thereof, where Y2 is C(R9). In some embodiments, provided herein are compounds of formula (I), or pharma- ceutically acceptable salts or solvates thereof, where Y2 is C(R9) and R9 is selected from hydrogen and C1-C6 alkyl. In some embodiments, provided herein are compounds of formula (I), or pharma- ceutically acceptable salts or solvates thereof, where Y2 is C(R9) and R9 is hydrogen. In some embodiments, provided herein are compounds of formula (I), or pharma- ceutically acceptable salts or solvates thereof, where Y2 is C(R9) and R9 is C1-C6 alkyl.

[0091] In some embodiments, provided herein are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R1 is:

[0092] [ka] In some embodiments, provided herein are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R1 is:

[0093] [ka] In some embodiments, provided herein are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R1 is:

[0094] [ka] In some embodiments, provided herein are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R1 is:

[0095] [ka] In some embodiments, provided herein are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R1 is:

[0096] [ka] It is.

[0097] In some embodiments, provided herein are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is:

[0098] [ka] In some embodiments, provided herein are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is:

[0099] [ka] where s is 1 and t is 1.

[0100] In some embodiments, provided herein are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is:

[0101] [ka] In some embodiments, provided herein are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is:

[0102] [ka] and q is 0. In some embodiments, provided herein are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is

[0103] [ka] And each R 13 is independently selected from halogen, C1-C6 alkyl, and C1-C6 haloalkyl. In some embodiments, provided herein are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is

[0104] [ka] q is 1, and R 13 is independently selected from halogen, C1-C6 alkyl, and C1-C6 haloalkyl. In some embodiments, provided herein are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein Z is N. In some embodiments, provided herein are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein Z is C(R 19 In some embodiments, provided herein are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein Z is C(R 19 ) and R 19is hydrogen, halogen, -CN, C1-C6 alkyl, or C1-C6 haloalkyl. In some embodiments, provided herein are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein Z is C(R 19 ) and R 19 In some embodiments, provided herein are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein Z is C(R 19 ) and R 19 In some embodiments, provided herein are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein Z is C(R 19 ) and R 19 In some embodiments, provided herein are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein Z is C(R 19 ) and R 19 In some embodiments, provided herein are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein Z is C(R 19 ) and R 19 In some embodiments, provided herein are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein Z is C(R 19 ) and R 19 In some embodiments, provided herein are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein Z is C(R 19 ) and R 19 In some embodiments, provided herein are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein Z is C(R 19 ) and R 19 is C1-C6 haloalkyl.

[0105] In some embodiments, provided herein are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is:

[0106] [ka] In some embodiments, provided herein are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is:

[0107] [ka] In some embodiments, provided herein are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is:

[0108] [ka] In some embodiments, provided herein are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is:

[0109] [ka] In some embodiments, provided herein are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is:

[0110] [ka] In some embodiments, provided herein are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is:

[0111] [ka] In some embodiments, provided herein are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is:

[0112] [ka] In some embodiments, provided herein are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is:

[0113] [ka] In some embodiments, provided herein are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is:

[0114] [ka] In some embodiments, provided herein are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is:

[0115] [ka] In some embodiments, provided herein are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is:

[0116] [ka] In some embodiments, provided herein are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is:

[0117] [ka] In some embodiments, provided herein are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is:

[0118] [ka] It is.

[0119] In some embodiments, provided herein are compounds of formula (I), or pharma- ceutically acceptable salts or solvates thereof, where X2 is -N(R5)-. In some embodiments, provided herein are compounds of formula (I), or pharma- ceutically acceptable salts or solvates thereof, where X2 is -N(R5)- and R5 is hydrogen. In some embodiments, provided herein are compounds of formula (I), or pharma- ceutically acceptable salts or solvates thereof, where X2 is -N(R5)- and R5 is C1-C6 alkyl. In some embodiments, provided herein are compounds of formula (I), or pharma- ceutically acceptable salts or solvates thereof, where X2 is -C(R5)2-. In some embodiments, provided herein are compounds of formula (I), or pharma- ceutically acceptable salts or solvates thereof, where X2 is -C(R5)2- and each R5 is hydrogen.

[0120] In some embodiments, provided herein are compounds of formula (I), or pharma- ceutically acceptable salts or solvates thereof, where X3 is -N(R5)-. In some embodiments, provided herein are compounds of formula (I), or pharma- ceutically acceptable salts or solvates thereof, where X3 is -N(R5)- and R5 is hydrogen. In some embodiments, provided herein are compounds of formula (I), or pharma- ceutically acceptable salts or solvates thereof, where X3 is -N(R5)- and R5 is C1-C6 alkyl. In some embodiments, provided herein are compounds of formula (I), or pharma- ceutically acceptable salts or solvates thereof, where X3 is -C(R5)2-. In some embodiments, provided herein are compounds of formula (I), or pharma- ceutically acceptable salts or solvates thereof, where X3 is -C(R5)2- and each R5 is hydrogen.

[0121] In some embodiments, provided herein are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, where X1 is O. In some embodiments, provided herein are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, where X1 is S. In some embodiments, provided herein are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, where X1 is N(R3). In some embodiments, provided herein are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, where X1 is C(NO2)(R4).

[0122] In some embodiments, provided herein is a compound of formula (Ia);

[0123] [ka] or a pharma- ceutically acceptable salt or solvate thereof, During the ceremony, Y1 is O, S, or N(R8); Y2 is N or C(R9); Y3 is O or N(R 10 ) and Z is N or C(R 19 ) and R1 is,

[0124] [ka] and R2 is

[0125] [ka] and R6 is -OH, -C1-C6 alkyl-OH, or -NH(R 16 ) and Each R7 is C1-C6 alkyl, -C1-C6 alkyl-CO2R 18 , C1-C6 haloalkyl, and C1-C6 heteroalkyl; or R6 and R7 combine to form a 5- or 6-membered heteroaryl ring; R8 is hydrogen, C1-C6 alkyl, or C1-C6 heteroalkyl; R9 is hydrogen, halogen, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 heteroalkyl; R 10 is -OH or -O-C1-C6 alkyl; R 11 is C1-C6 alkyl, R 12 is C1-C6 alkyl, Each R 13 is independently selected from halogen, C1-C6 alkyl, C1-C6 haloalkyl, and C1-C6 heteroalkyl; R 16 is hydrogen, C1-C6 alkyl or -C(O)-C1-C6 alkyl; R18 is hydrogen or C1-C6 alkyl; R 19 is hydrogen, halogen, -CN, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 heteroalkyl; Each R 20 is independently selected from C1-C6 alkyl, C1-C6 haloalkyl, and C1-C6 heteroalkyl; n is 1 or 2, p is 0, 1, 2, 3, or 4; q is 0, 1, or 2; s is 1, 2, or 3; t is 1, 2, or 3; and v is 0, 1, or 2;

[0126] Some embodiments are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein R1 is:

[0127] [ka] Some embodiments are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein R1 is:

[0128] [ka] Some embodiments are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein R1 is:

[0129] [ka] Some embodiments are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein R1 is:

[0130] [ka] Some embodiments are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein R1 is:

[0131] [ka] Some embodiments are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein R1 is:

[0132] [ka] Some embodiments are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein R1 is:

[0133] [ka] Some embodiments are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein R1 is:

[0134] [ka] It is.

[0135] Some embodiments are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, where R6 is -OH. Some embodiments are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, where R6 is -C1-C6 alkyl-OH. Some embodiments are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, where R6 is -NH(R 16Some embodiments are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein R6 is -NH(R 16 ) and R 16 is hydrogen. Some embodiments are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein R6 is -NH(R 16 ) and R 16 is C1-C6 alkyl. Some embodiments are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein R6 is -NH(R16) and R 16 is -C(O)-C1-C6 alkyl.

[0136] Some embodiments are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein each R7 is C1-C6 alkyl, -C1-C6 alkyl-CO2R 18 , C1-C6 haloalkyl, and C1-C6 heteroalkyl. Some embodiments are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein each R7 is independently selected from C1-C6 alkyl, -C1-C6 alkyl-CO2R 18 and C1-C6 haloalkyl. Some embodiments are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, where each R7 is independently selected from C1-C6 alkyl. Some embodiments are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, where each R7 is -CH3.

[0137] In some embodiments, provided herein is a compound of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, in which R6 and R7 combine to form a 5- or 6-membered heteroaryl ring. In some embodiments, provided herein is a compound of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, in which R6 and R7 combine to form a 5-membered heteroaryl ring selected from oxazolyl, thiazolyl, pyrazolyl, furanyl, thienyl, pyrrolyl, imidazolyl, triazolyl, tetrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, and thiadiazolyl. In some embodiments, provided herein is a compound of formula (Ia), or a pharma-ceutically acceptable salt or solvate thereof, in which R6 and R7 combine to form a 6-membered heteroaryl ring selected from pyridinyl, pyrimidinyl, pyrazinyl, and pyridazinyl.

[0138] In some embodiments, provided herein are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, where p is 0, 1, 2, or 3. In some embodiments, provided herein are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, where p is 0. In some embodiments, provided herein are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, where p is 1. In some embodiments, provided herein are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, where p is 2. In some embodiments, provided herein are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, where p is 3. In some embodiments, provided herein are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, where p is 4.

[0139] In some embodiments, provided herein are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, where n is 1. In some embodiments, provided herein are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, where n is 2.

[0140] In some embodiments, provided herein are compounds of Formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, where v is 0. In some embodiments, provided herein are compounds of Formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, where v is 2.

[0141] In some embodiments, provided herein are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein Y is O. In some embodiments, provided herein are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein Y is N(R 10 In some embodiments, provided herein are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein Y3 is N(R 10 ) and R 10 In some embodiments, provided herein are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein Y is N(R 10 ) and R 10 is -O-C1-C6 alkyl.

[0142] In some embodiments, provided herein are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, where Y1 is O. In some embodiments, provided herein are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, where Y1 is S. In some embodiments, provided herein are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, where Y1 is N(R8). In some embodiments, provided herein are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, where Y1 is N(R8), where R8 is hydrogen or C1-C6 alkyl.

[0143] In some embodiments, provided herein are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, where Y2 is N. In some embodiments, provided herein are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, where Y2 is C(R9). In some embodiments, provided herein are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, where Y2 is C(R9) and R9 is selected from hydrogen and C1-C6 alkyl. In some embodiments, provided herein are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, where Y2 is C(R9) and R 9 is hydrogen. In some embodiments, provided herein are compounds of Formula (Ia), or pharma- ceutically acceptable salts or solvates thereof, wherein Y2 is C(R9), and R9 is C1-C6 alkyl.

[0144] In some embodiments, provided herein are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein R1 is:

[0145] [ka] In some embodiments, provided herein are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein R1 is:

[0146] [ka] In some embodiments, provided herein are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein R1 is:

[0147] [ka] In some embodiments, provided herein are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein R1 is:

[0148] [ka] In some embodiments, provided herein are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein R1 is:

[0149] [ka] It is.

[0150] In some embodiments, provided herein are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is:

[0151] [ka] In some embodiments, provided herein are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is:

[0152] [ka] where s is 1 and t is 1.

[0153] In some embodiments, provided herein are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is:

[0154] [ka] In some embodiments, provided herein are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is:

[0155] [ka] and q is 0. In some embodiments, provided herein are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is

[0156] [ka] And each R 13 is independently selected from halogen, C1-C6 alkyl, and C1-C6 haloalkyl. In some embodiments, provided herein are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is

[0157] [ka] where q is 1 and R 13 is independently selected from halogen, C1-C6 alkyl, and C1-C6 haloalkyl. In some embodiments, provided herein are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein Z is N. In some embodiments, provided herein are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein Z is C(R 19 In some embodiments, provided herein are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein Z is C(R 19 ) and R 19 is hydrogen, halogen, -CN, C1-C6 alkyl, or C1-C6 haloalkyl. In some embodiments, provided herein are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein Z is C(R 19 ) and R 19 In some embodiments, provided herein are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein Z is C(R 19 ) and R 19 In some embodiments, provided herein are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein Z is C(R 19 ) and R 19 In some embodiments, provided herein are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein Z is C(R 19 ) and R 19 In some embodiments, provided herein are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein Z is C(R 19 ) and R 19In some embodiments, provided herein are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein Z is C(R 19 ) and R 19 In some embodiments, provided herein are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein Z is C(R 19 ) and R 19 In some embodiments, provided herein are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein Z is C(R 19 ) and R 19 is C1-C6 haloalkyl.

[0158] In some embodiments, provided herein are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is:

[0159] [ka] In some embodiments, provided herein are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is

[0160] [ka] In some embodiments, provided herein are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is

[0161] [ka] In some embodiments, provided herein are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is

[0162] [ka] In some embodiments, provided herein are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is

[0163] [ka] In some embodiments, provided herein are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is

[0164] [ka] In some embodiments, provided herein are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is

[0165] [ka] In some embodiments, provided herein are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is

[0166] [ka] In some embodiments, provided herein are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is

[0167] [ka] In some embodiments, provided herein are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is

[0168] [ka] In some embodiments, provided herein are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is

[0169] [ka] In some embodiments, provided herein are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is

[0170] [ka] In some embodiments, provided herein are compounds of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is

[0171] [ka] It is.

[0172] In some embodiments, provided herein is a compound of formula (Ib):

[0173] [ka] or a pharma- ceutically acceptable salt or solvate thereof, During the ceremony, Y1 is O; Y2 is C(R9); Y3 is O or N(R 10 ) and Z is N or C(R 19 ), R1 is,

[0174] [ka] and R2 is

[0175] [ka] and R6 is -OH, -C1-C6 alkyl-OH, or -NH(R 16 ) and Each R7 is C1-C6 alkyl, -C1-C6 alkyl-CO2R 18 , C1-C6 haloalkyl, and C1-C6 heteroalkyl; or R6 and R7 taken together form a 5- or 6-membered heteroaryl ring; R9 is hydrogen, halogen, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 heteroalkyl; R 10 is -OH or -O-C1-C6 alkyl; R 11 is C1-C6 alkyl, R 12 is C1-C6 alkyl, Each R 13 is independently selected from halogen, C1-C6 alkyl, C1-C6 haloalkyl, and C1-C6 heteroalkyl; R 16 is hydrogen, C1-C6 alkyl or -C(O)-C1-C6 alkyl; R 18 is hydrogen or C1-C6 alkyl, R 19 is hydrogen, halogen, -CN, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 heteroalkyl; n is 1 or 2, p is 0, 1, 2, 3, or 4; q is 0, 1, or 2; s is 1, 2, or 3; and t is 1, 2, or 3.

[0176] Some embodiments are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein R1 is

[0177] [ka] Some embodiments are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein R1 is

[0178] [ka] It is.

[0179] Some embodiments are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, where R6 is -OH. Some embodiments are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, where R6 is -C1-C6 alkyl-OH. Some embodiments are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, where R6 is -NH(R 16 Some embodiments are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein R6 is -NH(R 16 ) and R 16 is hydrogen. Some embodiments are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein R6 is -NH(R 16 ) and R 16 is C1-C6 alkyl. Some embodiments are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein R6 is -NH(R16 ) and R 16 is -C(O)-C1-C6 alkyl.

[0180] Some embodiments are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein each R7 is C1-C6 alkyl, -C1-C6 alkyl-CO2R 18 , C1-C6 haloalkyl, and C1-C6 heteroalkyl. Some embodiments are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein each R7 is independently selected from C1-C6 alkyl, -C1-C6 alkyl-CO2R 18 and C1-C6 haloalkyl. Some embodiments are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, where each R7 is independently selected from C1-C6 alkyl. Some embodiments are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, where each R7 is -CH3.

[0181] In some embodiments, provided herein is a compound of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, in which R6 and R7 combine to form a 5- or 6-membered heteroaryl ring. In some embodiments, provided herein is a compound of formula (Ib), or a pharma-ceutically acceptable salt or solvate thereof, in which R6 and R7 combine to form a 5-membered heteroaryl ring selected from oxazolyl, thiazolyl, pyrazolyl, furanyl, thienyl, pyrrolyl, imidazolyl, triazolyl, tetrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, and thiadiazolyl. In some embodiments, provided herein is a compound of formula (Ib), or a pharma-ceutically acceptable salt or solvate thereof, in which R6 and R7 combine to form a 6-membered heteroaryl ring selected from pyridinyl, pyrimidinyl, pyrazinyl, and pyridazinyl.

[0182] In some embodiments, provided herein are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, where p is 0, 1, 2, or 3. In some embodiments, provided herein are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, where p is 0. In some embodiments, provided herein are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, where p is 1. In some embodiments, provided herein are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, where p is 2. In some embodiments, provided herein are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, where p is 3. In some embodiments, provided herein are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, where p is 4.

[0183] In some embodiments, provided herein are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, where n is 1. In some embodiments, provided herein are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, where n is 2.

[0184] In some embodiments, provided herein are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein Y is O. In some embodiments, provided herein are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein Y is N(R 10 In some embodiments, provided herein are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein Y is N(R 10 ) and R 10In some embodiments, provided herein are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein Y is N(R 10 ) and R 10 is -O-C1-C6 alkyl.

[0185] In some embodiments, provided herein are compounds of formula (Ib), or pharma- ceutically acceptable salts or solvates thereof, wherein Y2 is C(R9) and R9 is selected from hydrogen and C1-C6 alkyl. In some embodiments, provided herein are compounds of formula (Ib), or pharma- ceutically acceptable salts or solvates thereof, wherein Y2 is C(R9) and R9 is hydrogen. In some embodiments, provided herein are compounds of formula (Ib), or pharma- ceutically acceptable salts or solvates thereof, wherein Y2 is C(R9) and R9 is C1-C6 alkyl.

[0186] In some embodiments, provided herein are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein R1 is:

[0187] [ka] In some embodiments, provided herein are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein R1 is:

[0188] [ka] In some embodiments, provided herein are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein R1 is:

[0189] [ka] In some embodiments, provided herein are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein R1 is:

[0190] [ka] In some embodiments, provided herein are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein R1 is:

[0191] [ka] In some embodiments, provided herein are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is:

[0192] [ka] In some embodiments, provided herein are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is:

[0193] [ka] where s is 1 and t is 1.

[0194] In some embodiments, provided herein are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is

[0195] [ka] In some embodiments, provided herein are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is:

[0196] [ka] and q is 0. In some embodiments, provided herein are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is

[0197] [ka] And each R 13 is independently selected from halogen, C1-C6 alkyl, and C1-C6 haloalkyl. In some embodiments, provided herein are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is

[0198] [ka] where q is 1 and R 13 is independently selected from halogen, C1-C6 alkyl, and C1-C6 haloalkyl. In some embodiments, provided herein are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein Z is N. Provided herein are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein Z is C(R 19 Provided herein are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein Z is C(R 19 ) and R 19is hydrogen, halogen, -CN, C1-C6 alkyl, or C1-C6 haloalkyl. In some embodiments, provided herein are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein Z is C(R 19 ) and R 19 In some embodiments, provided herein are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein Z is C(R 19 ) and R 19 In some embodiments, provided herein are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein Z is C(R 19 ) and R 19 In some embodiments, provided herein are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein Z is C(R 19 ) and R 19 In some embodiments, provided herein are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein Z is C(R 19 ) and R 19 In some embodiments, provided herein are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein Z is C(R 19 ) and R 19 In some embodiments, provided herein are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein Z is C(R 19 ) and R 19 In some embodiments, provided herein are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein Z is C(R 19 ) and R 19 is C1-C6 haloalkyl.

[0199] In some embodiments, provided herein are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is

[0200] [ka] In some embodiments, provided herein are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is

[0201] [ka] In some embodiments, provided herein are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is

[0202] [ka] In some embodiments, provided herein are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is

[0203] [ka] In some embodiments, provided herein are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is

[0204] [ka] In some embodiments, provided herein are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is

[0205] [ka] In some embodiments, provided herein are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is

[0206] [ka] In some embodiments, provided herein are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is

[0207] [ka] In some embodiments, provided herein are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is

[0208] [ka] In some embodiments, provided herein are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is

[0209] [ka] In some embodiments, provided herein are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is

[0210] [ka] In some embodiments, provided herein are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is

[0211] [ka] In some embodiments, provided herein are compounds of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is

[0212] [ka] It is.

[0213] In some embodiments, provided herein is a compound selected from the following, or a pharma- ceutically acceptable salt or solvate thereof:

[0214] [ka]

[0215] In some embodiments, provided herein is a compound selected from the following, or a pharma- ceutically acceptable salt or solvate thereof:

[0216] [ka]

[0217] In some embodiments, provided herein is a compound selected from the following, or a pharma- ceutically acceptable salt or solvate thereof:

[0218] [ka]

[0219] [ka]

[0220] Any combination of the above groups for the various variables is contemplated herein. Throughout the specification, groups and substituents can be chosen by one of ordinary skill in the art to provide stable moieties and compounds.

[0221] In some embodiments, the therapeutic agent (e.g., a compound of Formula (I), (Ia), or (Ib)) is present in the pharmaceutical composition as a pharma- ceutically acceptable salt. In some embodiments, any of the above compounds are suitable for any of the methods or compositions described herein.

[0222] Further forms of the compounds disclosed herein Isomers Furthermore, in some embodiments, the compounds described herein exist as geometric isomers. In some embodiments, the compounds described herein have one or more double bonds. The compounds presented herein include all cis, trans, syn, anti, entagene (E), and zusanmen (Z) isomers, and their corresponding mixtures. In some circumstances, the compounds exist as tautomers. The compounds described herein include all possible tautomers within the formulas described herein. In some circumstances, the compounds described herein have one or more chiral centers, and each center exists in the R or S configuration. The compounds described herein include all diastereomeric, enantiomeric, and epimeric forms, and their corresponding mixtures. In additional embodiments of the compounds and methods provided herein, mixtures of enantiomers and / or diastereomers resulting from a single preparation step, combination, or interconversion are useful for the applications described herein. In some embodiments, the compounds described herein are prepared as optically pure enantiomers by chiral chromatographic resolution of a racemic mixture. In some embodiments, the compounds described herein are prepared as their individual stereoisomers by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereomeric compounds, separating the diastereomers, and recovering the optically pure enantiomers. In some embodiments, separable complexes are preferred (e.g., crystalline diastereomeric salts). In some embodiments, the diastereomers have distinct physical properties (e.g., melting points, boiling points, solubility, reactivity, etc.) and are separated by taking advantage of these dissimilarities. In some embodiments, the diastereomers are separated by chiral chromatography or, preferably, by separation / resolution techniques based on differences in solubility. In some embodiments, the optically pure enantiomers are then recovered along with the resolving agent by any practical means that do not result in racemization.

[0223] labeled compound In some embodiments, the compounds described herein are present in their isotopically labeled form. In some embodiments, the methods disclosed herein include methods of treating disease by administering such isotopically labeled compounds. In some embodiments, the methods disclosed herein include methods of treating disease by administering such isotopically labeled compounds as pharmaceutical compositions. Thus, in some embodiments, the compounds disclosed herein include isotopically labeled compounds due to the fact that one or more atoms are replaced by atoms that are identical to those described herein but have atomic masses or mass numbers that are different from the atomic masses or mass numbers that are usually found in nature. Examples of isotopes that can be incorporated into the compounds described herein include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, and chloride, e.g., each of the isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, and chloride. 2 H, 3 H, 13 C. 14 C. 15 N, 17 O. 18 O. 31 P, 32 P, 35 S, 18 F, and 36 The compounds described herein, as well as pharma- ceutically acceptable salts, esters, solvates, hydrates, or derivatives thereof, that contain the aforementioned isotopes and / or other isotopes of other atoms, are within the scope of the present invention. Certain isotopically labeled compounds, e.g., 3 H and 14 Compounds incorporating a radioactive isotope, such as C, are useful in drug and / or substrate tissue distribution assays. Tritiated, i.e. 3 H, and carbon 14, i.e. 14 Isotopes such as C are particularly preferred for their ease of preparation and detectability. Additionally, heavier isotopes such as deuterium, i.e. 2Substitution with H produces certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced required dosage. In some embodiments, the isotopically labeled compound, a pharma- ceutically acceptable salt, ester, solvate, hydrate, or derivative thereof is prepared by any suitable method.

[0224] In some embodiments, the compounds described herein are labeled by other means, including but not limited to the use of chromophores or fluorescent moieties, bioluminescent labels, or chemiluminescent labels.

[0225] Pharmaceutically acceptable salts In some embodiments, the compounds described herein are present as their pharmaceutically acceptable salts. In some embodiments, the methods disclosed herein include methods of treating disease by administering such pharmaceutically acceptable salts. In some embodiments, the methods disclosed herein include methods of treating disease by administering such pharmaceutically acceptable salts as pharmaceutical compositions.

[0226] In some embodiments, the compounds described herein have acidic or basic groups and therefore react with any of a number of inorganic or organic bases, as well as inorganic and organic acids, to form pharma- ceutically acceptable salts. In some embodiments, these salts are prepared in situ during the final isolation and purification of the compounds described herein, or by separately reacting the purified compounds in free form with the appropriate acid or base and isolating the salt thus formed.

[0227] solvate In some embodiments, the compounds described herein exist as solvates. Some embodiments are methods of treating disease by administering such solvates. Further described herein are methods of treating disease by administering such solvates as pharmaceutical compositions.

[0228] Solvates contain either stoichiometric or non-stoichiometric amounts of solvent, and in some embodiments, are formed during the process of crystallization using pharma- ceutically acceptable solvents such as water, ethanol, etc. Hydrates are formed when the solvent is water, and alcoholates are formed when the solvent is alcohol. Solvates of the compounds described herein are conveniently prepared or formed during the process described herein. By way of example only, hydrates of the compounds described herein are conveniently prepared by recrystallization from aqueous / organic solvent mixtures using organic solvents, including but not limited to dioxane, tetrahydrofuran, or MeOH. Furthermore, the compounds provided herein exist in unsolvated as well as solvated forms. In general, solvated forms are considered equivalent to unsolvated forms for the purposes of the compounds and methods provided herein.

[0229] Compound synthesis In some embodiments, the synthesis of the compounds described herein is accomplished using means described in the chemical literature, using methods described herein, or by a combination thereof. Additionally, solvents, temperatures and other reaction conditions presented herein may be varied.

[0230] In other embodiments, the starting materials and reagents used in the synthesis of the compounds described herein are synthesized or obtained from commercial sources, such as, but not limited to, Sigma-Aldrich, Fischer Scientific (Fischer Chemicals), and Acros Organics.

[0231] In further embodiments, the compounds described herein, and other related compounds having different substituents, can be prepared by the techniques and materials described herein, as well as by other methods and techniques described in, for example, Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1-17 (John Wiley and Sons, 1991); Rodd's Chemistry of Carbon Compounds, Volumes 1-5 and Supplementals (Elsevier Science Publishers, 1989); Organic Reactions, Volumes 1-40 (John Wiley and Sons, 1991), Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989), March, Advanced Organic Chemistry 4th Ed., (Wiley 1992); Carey and Sundberg, Advanced Organic Chemistry 4 th Ed., Vols. A and B(Plenum 2000,2001), and Green and Wuts, Protective Groups in Organic Synthesis 3 rd Ed., (Wiley 1999) (all of which are incorporated by reference for such disclosure). The general preparation method of the compounds disclosed herein can be derived from reactions, which can be modified by using appropriate reagents and conditions for the introduction of various moieties found in the formulas provided herein. The following synthetic methods can be used as a guide.

[0232] Use of Protecting Groups In the reactions described, it may be necessary to protect reactive functional groups, such as hydroxy, amino, imino, thio or carboxy groups, which are desired in the final product to avoid their undesired participation in the reaction. Protecting groups are used to block some or all of the reactive moieties and prevent such groups from participating in chemical reactions until the protecting group is removed. Each protecting group is preferably removable by a different means. Protecting groups that are cleaved under completely different reaction conditions meet the requirement of differential removal.

[0233] Protecting groups can be removed by acid, base, reducing conditions (e.g., hydrogenolysis, etc.), and / or oxidative conditions. Groups such as trityl, dimethoxytrityl, acetal, t-butyldimethylsilyl, etc. are acid labile and can be used to protect carboxy and hydroxy reactive moieties in the presence of Cbz groups protected amino groups that are removable by hydrogenolysis, and Fmoc groups that are base labile. Carboxylic acid and hydroxy reactive moieties can be blocked with base labile groups such as methyl, ethyl, and acetyl, but not limited to, in the presence of amines blocked with acid labile groups such as t-butyl carbamate, or carbamates that are both acid and base stable, but hydrolytically removable.

[0234] Carboxylic acid and hydroxy reactive moieties can also be blocked with hydrolytically removable protecting groups such as benzyl groups, while amine groups capable of hydrogen bonding with acids can be blocked with base labile groups such as Fmoc. Carboxylic acid reactive moieties can be protected by conversion to simple ester compounds as exemplified herein, including conversion to alkyl esters, or they can be blocked with oxidatively removable protecting groups such as 2,4-dimethoxybenzyl, while coexisting amino groups can be blocked with fluoride labile silyl carbamates.

[0235] Allyl blocking groups are useful in the presence of acid and base protecting groups because the former are stable and can be subsequently removed by metal or pi-acid catalysis. For example, allyl-blocked carboxylic acids can be reacted with Pd 0 It can be deprotected by a catalytic reaction. Yet another form of protecting group is a resin to which a compound or intermediate can be attached. As long as the residue is attached to the resin, that functional group is blocked and cannot react. Once released from the resin, the functional group is available to react.

[0236] Typically, blocking / protecting groups are

[0237] [ka] may be selected from:

[0238] Detailed descriptions of other protecting groups, as well as techniques applicable to the creation of protecting groups and their removal, are described in Greene and Wuts, Protective Groups in Organic Synthesis, 3rd Ed., John Wiley & Sons, New York, NY, 1999, and Kocienski, Protective Groups, Thieme Verlag, New York, NY, 1994, which are incorporated herein by reference for such disclosures.

[0239] Treatment and prevention methods Some embodiments are methods of treating a metabolic disease in a patient in need of treatment, comprising administering to the patient a therapeutically effective amount of a compound of formula (I), (Ia), or (Ib), or a pharma- ceutically acceptable salt or solvate thereof. Some embodiments are methods of treating a metabolic disease in a patient in need of treatment, comprising administering to the patient a therapeutically effective amount of a compound of formula (I), (Ia), or (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein the metabolic disease is selected from type 2 diabetes, atherosclerosis, obesity, and gout. Some embodiments are methods of treating type 2 diabetes in a patient in need of treatment, comprising administering to the patient a therapeutically effective amount of a compound of formula (I), (Ia), or (Ib), or a pharma- ceutically acceptable salt or solvate thereof. Some embodiments are methods of treating atherosclerosis in a patient in need of treatment, comprising administering to the patient a therapeutically effective amount of a compound of formula (I), (Ia), or (Ib), or a pharma- ceutically acceptable salt or solvate thereof. Some embodiments are methods of treating obesity in a patient in need of such treatment comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (Ia), or (Ib), or a pharma- ceutically acceptable salt or solvate thereof.Some embodiments are methods of treating gout in a patient in need of such treatment comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (Ia), or (Ib), or a pharma- ceutically acceptable salt or solvate thereof.

[0240] Some embodiments are methods for treating liver disease in a patient in need of treatment, comprising administering to the patient a therapeutically effective amount of a compound of formula (I), (Ia), or (Ib), or a pharma- ceutically acceptable salt or solvate thereof.Some embodiments are methods for treating liver disease in a patient in need of treatment, comprising administering to the patient a therapeutically effective amount of a compound of formula (I), (Ia), or (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein the liver disease is selected from nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH), viral hepatitis, and cirrhosis.

[0241] Some embodiments are directed to a method of treating a pulmonary disease in a patient in need of treatment comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (Ia), or (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein the pulmonary disease is selected from asthma, chronic obstructive pulmonary disease (COPD), and idiopathic pulmonary fibrosis.

[0242] Some embodiments are methods of treating a central nervous system disease in a patient in need of treatment comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (Ia), or (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein the central nervous system disease is selected from Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis, and Parkinson's disease.

[0243] Some embodiments are methods of treating an inflammatory or autoimmune disease in a patient in need of treatment, comprising administering to the patient a therapeutically effective amount of a compound of formula (I), (Ia), or (Ib), or a pharma- ceutically acceptable salt or solvate thereof. Some embodiments are methods of treating an inflammatory or autoimmune disease in a patient in need of treatment, comprising administering to the patient a therapeutically effective amount of a compound of formula (I), (Ia), or (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein the inflammatory or autoimmune disease is selected from rheumatoid arthritis, multiple sclerosis, psoriasis, lupus, inflammatory bowel disease, Crohn's disease, and ulcerative colitis. Some embodiments are methods of treating an inflammatory or autoimmune disease in a patient in need of treatment, comprising administering to the patient a therapeutically effective amount of a compound of formula (I), (Ia), or (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein the disease is rheumatoid arthritis. Some embodiments are methods for treating an inflammatory or autoimmune disease in a patient in need of treatment, comprising administering to the patient a therapeutically effective amount of a compound of formula (I), (Ia), or (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein the disease is multiple sclerosis. Some embodiments are methods for treating an inflammatory or autoimmune disease in a patient in need of treatment, comprising administering to the patient a therapeutically effective amount of a compound of formula (I), (Ia), or (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein the disease is psoriasis. Some embodiments are methods for treating an inflammatory or autoimmune disease in a patient in need of treatment, comprising administering to the patient a therapeutically effective amount of a compound of formula (I), (Ia), or (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein the disease is lupus. Some embodiments are directed to a method of treating an inflammatory or autoimmune disease in a patient in need of treatment comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (Ia), or (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein the disease is inflammatory bowel disease.Some embodiments are methods of treating an inflammatory or autoimmune disease in a patient in need of treatment comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (Ia), or (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein the disease is Crohn's disease.Some embodiments are methods of treating an inflammatory or autoimmune disease in a patient in need of treatment comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (Ia), or (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein the disease is ulcerative colitis.

[0244] Some embodiments are methods of treating cardiovascular disease in a patient in need of treatment, comprising administering to the patient a therapeutically effective amount of a compound of formula (I), (Ia), or (Ib), or a pharmaceutically acceptable salt or solvate thereof. Some embodiments are methods of treating cardiovascular disease in a patient in need of treatment, comprising administering to the patient a therapeutically effective amount of a compound of formula (I), (Ia), or (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein the cardiovascular disease is atherosclerosis or stroke. Some embodiments are methods of treating atherosclerosis in a patient in need of treatment, comprising administering to the patient a therapeutically effective amount of a compound of formula (I), (Ia), or (Ib), or a pharmaceutically acceptable salt or solvate thereof. Some embodiments are methods of treating stroke in a patient in need of treatment, comprising administering to the patient a therapeutically effective amount of a compound of formula (I), (Ia), or (Ib), or a pharmaceutically acceptable salt or solvate thereof.

[0245] Pharmaceutical Compositions and Methods of Administration The NLRP3 inhibitor described herein is administered to the subject in a biologically compatible form suitable for administration to treat or prevent disease, disorder or condition.The administration of the NLRP3 inhibitor as described herein can be in any pharmacological form that comprises a therapeutically effective amount of the NLRP3 inhibitor alone or in combination with a pharmacologic acceptable carrier.

[0246] In certain embodiments, the compounds described herein are administered as pure chemicals.In other embodiments, the compounds described herein are combined with a pharma- ceutically suitable or acceptable carrier (also referred to herein as pharma- ceutically suitable (or acceptable) excipient, physiologically suitable (or acceptable) excipient, or physiologically suitable (or acceptable) carrier) selected based on the selected route of administration and standard pharmaceutical practice, for example as described in Remington: The Science and Practice of Pharmacy (Gennaro, 21st Ed. Mack Pub. Co., Easton, PA (2005)).

[0247] Thus, provided herein are pharmaceutical compositions comprising at least one compound described herein, or a pharma- ceutically acceptable salt, together with one or more pharma- ceutically acceptable carriers. A carrier(s) (or excipient(s)) is acceptable or suitable if it is compatible with the other components of the composition and not deleterious to the recipient (i.e., subject) of the composition.

[0248] Some embodiments are pharmaceutical compositions comprising a pharma- ceutically acceptable carrier and a compound of formula (I), (Ia), or (Ib), or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, a pharmaceutical composition comprises a pharma- ceutically acceptable carrier and a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof. Some embodiments are pharmaceutical compositions comprising a pharma- ceutically acceptable carrier and a compound of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof. Some embodiments are pharmaceutical compositions comprising a pharma- ceutically acceptable carrier and a compound of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof.

[0249] Another embodiment provides a pharmaceutical composition consisting essentially of a pharma- ceutically acceptable carrier and a compound of formula (I), (Ia), or (Ib), or a pharma- ceutically acceptable salt or solvate thereof. Some embodiments are pharmaceutical compositions consisting essentially of a pharma- ceutically acceptable carrier and a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments are pharmaceutical compositions consisting essentially of a pharma- ceutically acceptable carrier and a compound of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof. Some embodiments are pharmaceutical compositions consisting essentially of a pharma- ceutically acceptable carrier and a compound of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof.

[0250] In certain embodiments, the compounds described herein are substantially pure, in that they contain less than about 5%, or less than about 1%, or less than about 0.1%, of other small organic molecules, such as contaminating intermediates or by-products, e.g., produced in one or more steps of a synthetic method.

[0251] These formulations include those suitable for oral, topical, buccal, parenteral (eg, subcutaneous, intramuscular, intradermal, or intravenous) or aerosol administration.

[0252] Exemplary pharmaceutical compositions are used in solid, semi-solid or liquid form, containing one or more disclosed compounds as active ingredients in a mixture with organic or inorganic carriers or excipients suitable for external, enteral or parenteral use. In some embodiments, the active ingredient is compounded with a conventional non-toxic pharma- ceutically acceptable carrier for, for example, tablets, pellets, capsules, suppositories, solutions, emulsions, suspensions, and any other form suitable for use. The active subject compound is included in the pharmaceutical composition in an amount sufficient to produce the desired effect on the disease process or condition.

[0253] In some embodiments, the NLRP3 inhibitor described herein is administered to a subject in a biologically compatible form suitable for topical administration to treat or prevent skin diseases, disorders, or conditions. "Biologically compatible form suitable for topical administration" refers to a form of the NLRP3 inhibitor administered in which the therapeutic effect of the inhibitor is greater than the toxic effects. The administration of the NLRP3 inhibitor described herein can be in any pharmacological form that includes a therapeutically effective amount of the NLRP3 inhibitor alone or in combination with a pharma- ceutically acceptable carrier.

[0254] The topical administration of NLRP3 inhibitors can be presented in the form of aerosol, semi-solid pharmaceutical composition, powder, or solution.The term "semi-solid composition" refers to ointment, cream, salve, jelly, or other pharmaceutical composition of substantially similar consistency suitable for application to skin.Examples of semi-solid compositions are described in Chapter 17 of Theory and Practice of Industrial Pharmacy, Lachman, Lieberman Kanig, published by Lea and Febiger (1970), and Chapter 67 of Remington's Pharmaceutical Sciences, 15th Edition (1975), published by Mack Publishing Company.

[0255] Dermal or skin patches are another method for transdermal delivery of the therapeutic or pharmaceutical compositions described herein. The patch can provide an absorption enhancer, such as DMSO, to enhance absorption of the compound. The patch can include a patch that controls the rate of drug delivery to the skin. The patch can provide various administration systems, including a reservoir system or a monolithic system, respectively. The reservoir design can have four layers, for example, an adhesive layer that directly contacts the skin, a control membrane that controls the diffusion of the drug molecules, a reservoir of drug molecules, and a water-resistant backing. Such a design delivers a uniform amount of drug over a specified period of time, and the delivery rate must be lower than the saturation limit of different types of skin. For example, a monolithic design usually has only three layers: an adhesive layer, a polymer matrix containing the compound, and a waterproof backing. This design brings a saturating amount of drug to the skin. The delivery is thereby controlled by the skin. If the amount of drug in the patch decreases below the saturation level, the delivery rate will decrease.

[0256] In one embodiment, the topical composition may take the form of, for example, a hydrogel based on polyacrylic acid or polyacrylamide, as an ointment, for example using polyethylene glycol (PEG) as carrier, such as the standard ointment DAB 8 (50% PEG 300, 50% PEG 1500), or as an emulsion, in particular as a microemulsion based on water-in-oil or oil-in-water, optionally with the addition of liposomes. Suitable permeation enhancers (entrainers) include sulfoxide derivatives such as dimethyl sulfoxide (DMSO) or decyl methyl sulfoxide (decyl-MSO) and transcutol (diethylene glycol monoethyl ether) or cyclodextrins, as well as pyrrolidones, e.g., 2-pyrrolidone, N-methyl-2-pyrrolidone, 2-pyrrolidone-5-carboxylic acid, or biodegradable N-(2-hydroxyethyl)-2-pyrrolidone and their fatty acid esters; urea derivatives, such as dodecyl urea, 1,3-didodecyl urea, and 1,3-diphenyl urea; and terpenes, e.g., D-limonene, menthone, α-terpinol, carbol, limonene oxide, or 1,8-cineole.

[0257] Ointments, pastes, creams and gels can also contain excipients such as starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonite, silicic acid, and talc, or mixtures thereof. Powders and sprays can also contain excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicate and polyamide powder, or mixtures of these substances. Solutions of nanocrystalline antimicrobial metals can be converted into aerosols or sprays by any of the known means routinely used for the manufacture of aerosol pharmaceuticals. In general, such methods involve pressurizing, or providing a means for pressurizing, a container of the solution, usually with an inert carrier gas, and forcing the pressurized gas through a small orifice. Sprays can additionally contain conventional propellants such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons such as butane and propane.

[0258] The carrier may also include other pharma- ceutically acceptable excipients to modify or maintain the pH, osmolality, viscosity, clarity, color, sterility, stability, dissolution rate, or odor of the formulation. The anti-skin aging composition may also further include antioxidants, sunscreens, natural retinoids (e.g., retinol), and other additives commonly found in skin treatment compositions.

[0259] In some embodiments for preparing solid compositions such as tablets, the primary active ingredient is mixed with a pharmaceutical carrier, e.g., conventional tablet ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g., water, to form a solid preformulation composition containing a homogenous mixture of the disclosed compound or a non-toxic pharmaceutically acceptable salt thereof. When these preformulation compositions are referred to as homogenous, it is meant that the active ingredient is evenly dispersed throughout the composition such that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills, and capsules.

[0260] In solid dosage forms for oral administration (capsules, tablets, pills, dragees, powders, granules, etc.), the subject compositions are mixed with one or more pharma- ceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and / or any of the following: (1) fillers or extenders, such as starch, cellulose, microcrystalline cellulose, silicified microcrystalline cellulose, lactose, sucrose, glucose, mannitol, and / or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, hypromellose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and / or acacia; (3) humectants, such as glycerol; (4) crospoyl phosphate; (5) glycerol; (6) glycerol; (7) glycerol; (8) glycerol; (9) glycerol; (10) glycerol; (11) glycerol; (12) glycerol; (13) glycerol; (14) glycerol; (15) glycerol; (16) glycerol; (17) glycerol; (18) glycerol; (19) glycerol; (20) glycerol; (21) glycerol; (22) glycerol; (23) glycerol; (24) glycerol; (25) glycerol; (26) glycerol; (27) glycerol; (28) glycerol; (29) glycerol; (30) glycerol; (31) glycerol; (32) glycerol; (33) glycerol; (34) glycerol; (35) glycerol; (36) glycerol; (37) glycerol; (38) glycerol; ( Disintegrating agents such as vidone, croscarmellose sodium, sodium starch glycolate, agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, (5) solution retarding agents such as paraffin, (6) absorption accelerators such as quaternary ammonium compounds, (7) wetting agents such as, for example, docusate sodium, cetyl alcohol, and glycerol monostearate, (8) absorbents such as kaolin and bentonite clay, (9) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof, and (10) coloring agents. For capsules, tablets, and pills, in some embodiments, the composition includes a buffering agent. In some embodiments, solid compositions of a similar type are also used as fillers for soft and hard-filled gelatin capsules, using excipients such as lactose or milk sugar, and high molecular weight polyethylene glycols, and the like.

[0261] In some embodiments, tablets are made by compression or molding, optionally with one or more accessory ingredients. In some embodiments, compressed tablets are prepared using binders (e.g., gelatin or hydroxypropylmethylcellulose), lubricants, inert diluents, preservatives, disintegrants (e.g., sodium starch glycolate or cross-linked sodium carboxymethylcellulose), surface active agents or dispersants. In some embodiments, molded tablets are made by molding a mixture of the subject composition moistened with an inert liquid diluent in a suitable machine. In some embodiments, tablets and other solid dosage forms such as dragees, capsules, pills and granules are scored or prepared with coatings and shells, such as enteric coatings and other coatings.

[0262] Compositions for inhalation or insufflation include solutions and suspensions in pharma- ceutically acceptable aqueous or organic solvents, or mixtures thereof, and powders.Liquid dosage forms for oral administration include pharma-ceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, and elixirs.In addition to the subject compositions, in some embodiments, liquid dosage forms include inert diluents, such as water or other solvents, solubilizers, and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (especially cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil, sesame oil), glycerol, tetrahydrofuryl alcohol, polyethylene glycol, fatty acid esters of sorbitan, cyclodextrins, and mixtures thereof.

[0263] In some embodiments, suspensions contain, in addition to the subject composition, suspending agents such as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, metahydroxyaluminum, bentonite, agar, and tragacanth, and mixtures thereof.

[0264] In some embodiments, powders and sprays contain, in addition to the subject composition, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicate, and polyamide powder, or mixtures of these substances. In some embodiments, sprays further contain conventional propellants such as chlorofluorohydrocarbons, and volatile unsubstituted hydrocarbons such as butane and propane.

[0265] Alternatively, the compositions and compounds disclosed herein are administered by aerosol. This is accomplished by preparing aqueous aerosols, liposomal preparations, or solid particles containing the compounds. In some embodiments, non-aqueous (e.g., fluorocarbon propellant) suspensions are used. In some embodiments, sonic nebulizers are used because they minimize exposing the agent to shear that can cause degradation of the compounds contained in the subject composition. Typically, aqueous aerosols are made by formulating an aqueous solution or suspension of the subject composition with conventional pharma- ceutically acceptable carriers and stabilizers. Carriers and stabilizers vary according to the requirements of the particular subject composition, but typically include non-ionic surfactants (Tween, Pluronic, or polyethylene glycol), innocuous proteins such as serum albumin, sorbitan esters, amino acids such as oleic acid, lecithin, glycine, buffers, salts, sugars, or sugar alcohols, and the like. Aerosols are generally prepared from isotonic solutions.

[0266] Pharmaceutical compositions suitable for parenteral administration include the subject compositions in combination with one or more pharma- ceutically acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders to be reconstituted into sterile injectable solutions or dispersions immediately prior to use, which in some embodiments contain antioxidants, buffers, bacteriostats, solutes that render the formulation isotonic with the blood of the intended recipient, or suspending or thickening agents.

[0267] Examples of suitable aqueous and non-aqueous carriers used in pharmaceutical compositions include water, ethanol, polyols (e.g., glycerol, propylene glycol, polyethylene glycol, etc.) and suitable mixtures thereof, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate and cyclodextrin. Proper fluidity is maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

[0268] The dosage of a composition comprising at least one compound described herein will vary depending on the patient's (e.g., human) condition, i.e., stage of the disease, general health, age, and other factors.

[0269] The pharmaceutical composition is administered in a manner appropriate for the disease to be treated (or prevented). The appropriate dose and the appropriate duration and frequency of administration are determined by factors such as the patient's condition, the type and severity of the patient's disease, the specific form of the active ingredient, and the method of administration. In general, the appropriate dose and treatment regimen provides a sufficient amount of the composition to provide therapeutic and / or prophylactic benefits (e.g., more frequent complete or partial remissions, or longer disease-free and / or overall survival, or improved clinical outcomes such as reduced severity of symptoms). The optimal dose is generally determined using experimental models and / or clinical trials. In some embodiments, the optimal dose depends on the patient's body weight, weight, or blood volume.

[0270] Oral doses typically range from about 1.0 mg to about 1000 mg, 1 to 4 times or more per day.

[0271] Dose administration can be repeated depending on the pharmacokinetic parameters of the dosage form and the route of administration used.

[0272] It is particularly advantageous to formulate compositions in dosage unit form for ease of administration and uniformity of dosage. As used herein, dosage unit form refers to physically discrete units suitable as single dosages for the mammalian subject to be treated, each unit containing a predetermined amount of active compound calculated to produce a desired therapeutic effect in association with the required pharmaceutical carrier. The specifications of the dosage unit form are determined by and directly depend on (a) the unique characteristics of the NLRP3 inhibitor and the specific therapeutic effect to be achieved, and (b) the inherent limitations of the art of compounding such active compounds for the treatment of sensitivity in an individual. The specific dose can be easily calculated by those skilled in the art according to, for example, the approximate body weight or body surface area of ​​the patient, or the volume of the body space to be occupied. The dose is also calculated according to the specific route of administration selected. Further refinement of the calculations required to determine the appropriate dosage for treatment is routinely performed by those skilled in the art. Such calculations can be performed without undue experimentation by those skilled in the art in light of the NLRP3 inhibitor activity disclosed herein in the assay preparation of target cells. The exact dosage is determined in conjunction with standard dose-response studies. It will be understood that the amount of composition actually administered will be determined by the practitioner in light of the relevant circumstances, including the condition or conditions being treated, the choice of composition to be administered, the age, weight, and response of the particular patient, the severity of the patient's symptoms, and the selected route of administration.

[0273] The toxicity and therapeutic efficacy of such NLRP3 inhibitors are discussed, for example, in LD 50 (lethal dose for 50% of the population) and ED 50 The LD (the dose that is therapeutically effective in 50% of the population) can be determined by standard pharmaceutical procedures in cell cultures or experimental animals. The dose ratio between toxic and therapeutic effects is the therapeutic index, and the LD 50 / ED 50The therapeutic index can be expressed as a ratio of NLRP3 inhibitors to NLRP3 inhibitors. NLRP3 inhibitors that exhibit large therapeutic indices are preferred. Although NLRP3 inhibitors that exhibit toxic side effects can be used, care should be taken to design a delivery system that targets such inhibitors to the site of diseased tissues in order to minimize potential damage to uninfected cells, thereby reducing side effects.

[0274] Data obtained from cell culture assays and animal studies can be used to formulate a range of dosages for use in humans. Such dosages of NLRP3 inhibitors can be used to administer ED with little or no toxicity. 50 The circulating concentration of NLRP3 inhibitors is preferably within a range including the IC 2 . The dosage may vary within this range depending on the dosage form used and the route of administration utilized. For any NLRP3 inhibitor used in the methods described herein, the therapeutically effective dose can be initially estimated from cell culture assays. The IC 2 , determined in cell culture, is used as the IC 2 . 50 Doses can be formulated in animal models to achieve a circulating plasma concentration range that includes (i.e., the concentration of NLRP3 inhibitor that achieves half-maximal inhibition of symptoms). Such information can be used to more accurately determine useful doses in humans. Levels in plasma can be measured, for example, by high performance liquid chromatography. EXAMPLES

[0275] The following examples are provided for illustrative purposes and are not intended to limit the scope of the claims provided herein.All references in these examples and throughout this specification are incorporated herein by reference for all legal purposes provided thereby.The starting materials and reagents used for the synthesis of the compounds described herein can be synthesized or obtained from commercial sources such as, but not limited to, Sigma-Aldrich, Acros Organics, Fluka, and Fischer Scientific.

[0276] Standard abbreviations and acronyms are used herein as defined in J. Org. Chem. 2007 72(1):23A-24A. Other abbreviations and acronyms are as follows:

[0277] [Table 1]

[0278] Example 1: Synthesis of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-hydroxy-4-methyl-5,6,7,8-tetrahydro-4H-5,8-methanocyclohepta[b]furan-2-sulfonamide (6)

[0279] [ka]

[0280] 1,2,3,5,6,7-Hexahydro-s-indacene-4-amine (2 g, 1.0 equiv.) and trimethylamine (2.26 mL, 1.2 equiv.) were dissolved in dry THF (50 mL). To this solution was added triphosgene (1.14 g, 0.33 equiv.) at 0° C. The resulting mixture was stirred at room temperature for 5 minutes, and then the reaction was heated at 85° C. in a sealed tube for 2 hours. The reaction mixture was cooled to room temperature and the THF was removed in vacuo. The residue was suspended in dry hexane (100 mL) and filtered through a 2-inch pad of silica gel. The filtrate was concentrated in vacuo to give white crystalline 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (1) (1.88 g, 81%).

[0281] To a cooled (0°C) solution of sodium bicarbonate (3.53 g, 42 mmol) and chloroacetaldehyde (6.6 g of a 50 wt% solution in water) in water (50 mL) was added a solution of bicyclo[3.2.1]octane-2,4-dione (4.88 g, 35 mmol) in water (30 mL) and DMF (15 mL) dropwise at a rate of 1 mL / min. The mixture was stirred at room temperature for 18 h and ethyl acetate (100 mL) was added. The pH was adjusted to approximately 1 with 50% H2SO4 and the resulting mixture was stirred vigorously for 3 h. The organic layer was collected and the acidic layer was extracted with ethyl acetate (3 x 40 mL). The combined organic extracts were washed with water, saturated NaHCO3, brine and dried over Na2SO4. The solvent was evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel to give 5,6,7,8-tetrahydro-4H-5,8-methanocyclohepta[b]furan-4-one (2) (1.06 g).

[0282] A solution of 5,6,7,8-tetrahydro-4H-5,8-methanocyclohepta[b]furan-4-one (2) (1.0 g, 1.0 equiv.) in methylene chloride (10 mL) was cooled to -10°C under N2 and chlorosulfonic acid (0.72 g, 1.0 equiv.) was added dropwise over 2 min. The cooling bath was removed and the reaction was stirred at room temperature under N2 for 18 h. The reaction mixture was cooled to -10°C and pyridine (540 mg, 1.1 equiv.) was added dropwise. The reaction was stirred at -10°C for 30 min and then solid PCl5 (1.4 g, 1.1 equiv.) was added. After stirring at <0°C for 30 min, the cooling bath was removed and the reaction was stirred at room temperature overnight. The reaction mixture was cooled to 0°C and quenched by addition of ice water. The mixture was stirred for 30 min. The methylene chloride layer was separated and the aqueous phase was extracted with methylene chloride (20 mL). The combined organic layers were washed with water and dried over sodium sulfate. The solution was evaporated in vacuo to give crude 4-oxo-5,6,7,8-tetrahydro-4H-5,8-methanocyclohepta[b]furan-2-sulfonyl chloride (3) (1.6 g).

[0283] To a solution of crude 4-oxo-5,6,7,8-tetrahydro-4H-5,8-methanocyclohepta[b]furan-2-sulfonyl chloride (3) (1.6 g) in THF (10 mL) was added concentrated NH4OH (3 mL). The resulting mixture was stirred at room temperature for 3 h. The reaction was diluted with 50 mL of ethyl acetate and washed with water (2 x 30 mL). The crude mixture was purified by column chromatography to give 4-oxo-5,6,7,8-tetrahydro-4H-5,8-methanocyclohepta[b]furan-2-sulfonamide (4) (942 mg, 58%).

[0284] To a solution of 4-oxo-5,6,7,8-tetrahydro-4H-5,8-methanocyclohepta[b]furan-2-sulfonamide (4) (100 mg, 1.0 equiv.) in THF (2 mL) at 0° C. was added MeMgCl (1 mL, 3M in THF). The resulting mixture was stirred at room temperature for 3 h. The reaction was quenched with 1N HCl at 0° C. and extracted with ethyl acetate (2×15 mL). The crude mixture was purified on a silica gel column to give 4-hydroxy-4-methyl-5,6,7,8-tetrahydro-4H-5,8-methanocyclohepta[b]furan-2-sulfonamide (5) (87 mg).

[0285] To a solution of 4-hydroxy-4-methyl-5,6,7,8-tetrahydrofuran-4H-5,8-methanocyclohepta[b]furan-2-sulfonamide (5) (58 mg, 1.0 equiv.) in anhydrous THF (4 mL) was added powdered sodium t-butoxide (21 mg, 1.0 equiv.). The mixture was stirred at room temperature for 15 min, then 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (1) (45 mg, 1.0 equiv.) in dry THF (1 mL) was added dropwise. The resulting mixture was stirred at room temperature for 2 h. The solvent was removed in vacuo. The residue was suspended in ethyl acetate (30 mL) and washed with 1 N HCl (3×20 mL), water, and brine. The crude mixture was purified on a silica gel column to give N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-hydroxy-4-methyl-5,6,7,8-tetrahydro-4H-5,8-methanocyclohepta[b]furan-2-sulfonamide (6) (25 mg) as a white solid. LCMS: 457.4 (M+H). + .

[0286] Example 2: Synthesis of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-oxo-5,6,7,8-tetrahydro-4H-5,8-methanocyclohepta[b]furan-2-sulfonamide (7)

[0287] [ka]

[0288] N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-oxo-5,6,7,8-tetrahydro-4H-5,8-methanocyclohepta[b]furan-2-sulfonamide (7) was prepared in a similar manner as described in the last step of Example 1 by replacing 4-hydroxy-4-methyl-5,6,7,8-tetrahydro-4H-5,8-methanocyclohepta[b]furan-2-sulfonamide (5) with 4-oxo-5,6,7,8-tetrahydro-4H-5,8-methanocyclohepta[b]furan-2-sulfonamide (4). LCMS: 441.0 (M+H). + .

[0289] Example 3: Synthesis of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-hydroxy-5,6,7,8-tetrahydro-4H-5,8-methanocyclohepta[b]furan-2-sulfonamide (9)

[0290] [ka]

[0291] To a solution of 4-oxo-5-6,7,8-tetrahydro-4H-5,8-methanocyclohepta[b]furan-2-sulfonamide (4) (100 mg, 1.0 equiv.) in MeOH (4 mL) at 0° C. was added NaBH4 (30 mg, 2.0 equiv.). The resulting mixture was stirred at 0° C. for 1 h. The reaction was quenched with 1N HCl at 0° C. and the mixture was extracted with ethyl acetate (2×15 mL). The crude mixture was purified by column chromatography to give 4-hydroxy-5,6,7,8-tetrahydro-4H-5,8-methanocyclohepta[b]furan-2-sulfonamide (8) (78 mg).

[0292] N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-hydroxy-5,6,7,8-tetrahydro-4H-5,8-methanocyclohepta[b]furan-2-sulfonamide (9) was prepared in a similar manner as described in the last step of Example 1 by replacing 4-hydroxy-4-methyl-5,6,7,8-tetrahydro-4H-5,8-methanocyclohepta[b]furan-2-sulfonamide (5) with 4-hydroxy-5,6,7,8-tetrahydro-4H-5,8-methanocyclohepta[b]furan-2-sulfonamide (8). LCMS: 443.1 (M+H). + .

[0293] Example 4: Synthesis of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-(hydroxyimino)-5,6,7,8-tetrahydro-4H-5,8-methanocyclohepta[b]furan-2-sulfonamide (11)

[0294] [ka]

[0295] 4-Oxo-5,6,7,8-tetrahydro-4H-5,8-methanocyclohepta[b]furan-2-sulfonamide (100 mg, 1.0 equiv.) and NH2OH 50 wt.% in water (82 mg, 3.0 equiv.) were dissolved in EtOH (5 mL). One drop of acetic acid was added to the solution. The resulting mixture was heated at 80° C. for 15 h. The solvent was removed in vacuo. The residue was dissolved in ethyl acetate (40 mL), washed with water and brine, and purified on a silica gel column to give (E / Z mixture) 4-(hydroxyimino)-5,6,7,8-tetrahydro-4H-5,8-methanocyclohepta[b]furan-2-sulfonamide (10) (79 mg).

[0296] N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-(hydroxyimino)-5,6,7,8-tetrahydro-4H-5,8-methanocyclohepta[b]furan-2-sulfonamide (11) was prepared in a similar manner as described in the last step of Example 1 by replacing 4-hydroxy-4-methyl-5,6,7,8-tetrahydro-4H-5,8-methanocyclohepta[b]furan-2-sulfonamide (5) with 4-(hydroxyimino)-5,6,7,8-tetrahydro-4H-5,8-methanocyclohepta[b]furan-2-sulfonamide (10). LCMS: 456.1 (M+H). + .

[0297] Example 5: Synthesis of 2-(2,6-diisopropylphenyl)-N-((4-oxo-5,6,7,8-tetrahydro-4H-5,8-methanocyclohepta[b]furan-2-yl)sulfonyl)acetamide (14)

[0298] [ka]

[0299] To a solution of 2-bromo-1,3-diisopropylbenzene (1.0 g, 1.0 equiv.) in dry THF (20 mL) was added Pd(tBu3P)2 (420 mg, 0.2 equiv.). The mixture was degassed by bubbling N2 for 5 min, then (2-ethoxy-2-oxoethyl)zinc(II) bromide (0.5 M in THF, 16.5 mL, 2.0 equiv.) was added. The resulting mixture was heated at 65° C. for 30 min. The reaction was quenched with saturated NH4Cl and extracted with ethyl acetate (2×40 mL). The organic phase was concentrated in vacuo. The crude mixture was purified on a silica gel column to give ethyl 2-(2,6-diisopropylphenyl)acetate (12) (1.0 g).

[0300] To a solution of ethyl 2-(2,6-diisopropylphenyl)acetate (12) (1.0 g) in THF (10 mL) was added 2N NaOH (30 mL). The mixture was heated at 80° C. for 1 h. The THF was removed in vacuo and then the pH was adjusted to 1 with concentrated HCl. The mixture was extracted with ethyl acetate (2×30 mL) to give 2-(2,6-diisopropylphenyl)acetic acid (13) (0.81 g).

[0301] To a solution of 2-(2,6-diisopropylphenyl)acetic acid (13) (55 mg, 1.0 equiv.) in DMF (5 mL) was added HBTU (100 mg, 1.05 equiv.) and DIEA (50 mg, 1.5 equiv.) at 0° C. The mixture was stirred at 0° C. for 15 min, and then 4-oxo-5,6,7,8-tetrahydro-4H-5,8-methanocyclohepta[b]furan-2-sulfonamide (4) (60 mg, 1.0 equiv.) was added. The resulting mixture was stirred at room temperature for 5 h. The reaction mixture was diluted with ethyl acetate (30 mL) and washed with water (3×20 mL) and brine. The crude mixture was purified on a silica gel column to give 2-(2,6-diisopropylphenyl)-N-((4-oxo-5,6,7,8-tetrahydro-4H-5,8-methanocyclohepta[b]furan-2-yl)sulfonyl)acetamide (14) (85 mg, 77%). LCMS: 444.2 (M+H). + .

[0302] Example 6: Synthesis of 2-(2,6-diisopropylphenyl)-N-((4-hydroxy-5,6,7,8-tetrahydro-4H-5,8-methanocyclohepta[b]furan-2-yl)sulfonyl)acetamide (15)

[0303] [ka]

[0304] To 2-(2,6-diisopropylphenyl)-N-((4-oxo-5,6,7,8-tetrahydro-4H-5,8-methanocyclohepta[b]furan-2-yl)sulfonyl)acetamide (14) (30 mg, 1.0 equiv.) in MeOH (4 mL) at 0° C. was added NaBH4 (11 mg, 5.0 equiv.). The resulting mixture was stirred at 0° C. for 1 h. The reaction was quenched with 1N HCl at 0° C. and the mixture was extracted with ethyl acetate (2×10 mL). The crude mixture was purified by column chromatography to give 2-(2,6-diisopropylphenyl)-N-((4-hydroxy-5,6,7,8-tetrahydro-4H-5,8-methanocyclohepta[b]furan-2-yl)sulfonyl)acetamide (15) (18 mg). LCMS: 446.0 (M+H) + .

[0305] Example 7: Synthesis of 2-(2,6-diisopropylphenyl)-N-((4-hydroxy-4-methyl-5,6,7,8-tetrahydro-4H-5,8-methanocyclohepta[b]furan-2-yl)sulfonyl)acetamide (16)

[0306] [ka]

[0307] To 2-(2,6-diisopropylphenyl)-N-((4-oxo-5,6,7,8-tetrahydro-4H-5,8-methanocyclohepta[b]furan-2-yl)sulfonyl)acetamide (14) (30 mg, 1.0 equiv.) in THF (2 mL) at 0° C. was added MeMgCl (0.2 mL, 3M in THF). The resulting mixture was stirred at room temperature for 3 h. The reaction was quenched with 1N HCl at 0° C. and extracted with ethyl acetate (2×10 mL). The crude mixture was purified on a silica gel column to give 2-(2,6-diisopropylphenyl)-N-((4-hydroxy-4-methyl-5,6,7,8-tetrahydro-4H-5,8-methanocyclohepta)[b]furan-2-yl)sulfonyl)acetamide (16) (17 mg). LCMS: 460.3 (M+H) + .

[0308] Compounds 17-20 were prepared by procedures similar to those described in the previous examples.

[0309] [Table 2] JPEG0007595642000124.jpg249170 JPEG0007595642000125.jpg251170 JPEG0007595642000126.jpg197170

[0310] Example 8: Mouse BMDMIL-1b Assay Mouse bone marrow cells from C57BL6 tibias and femurs were cultured in complete Isocove's medium supplemented with 20 ng / mL MCFS (BMDM medium) at a density of 50 million cells / 15 cm Petri dish. Fresh medium was replaced every 3 days, and bone marrow-derived macrophages were collected, washed, and counted on day 7. Cells were plated at 5 × 10 per well in 100 μL of BMDM medium. 4 Cells were seeded in 96-well plates at a density of 1000 x 1000 and cultured overnight. Cells were stimulated with 200ng / mL Ultrapure LPS-B5 at 37°C for 3 hours before the addition of pre-diluted compounds. 30 minutes after compound addition, 5mM ATP was added for a secondary stimulation for 45 minutes. After stimulation, plates were spun down briefly and 50μL of supernatant was taken from each well. ELISA for mouse IL-1b was performed with 1:10 and 1:100 diluted supernatants using a pre-coated kit. IL-1b concentrations were calculated based on pre-titrated standards and compound inhibitory IC50s were generated using the Levenberg Marquardt damped least squares method.

[0311] [Table 3]

[0312] Example 9: Human Monocyte IL-1b Assay Human PBMCs were harvested from fresh donor blood using a Ficoll gradient. 50 million PBMC cells in 10 mL RPMI were plated in a 15 cm non-tissue culture treated Petri dish and incubated at 37°C for 1 h. At the end of the incubation, the medium was gently rocked to remove non-adherent cells. Adherent cells were harvested by gentle scraping and counted. Enriched adherent cells were collected at 2 × 10 per well. 4 Cells were plated in 96-well plates and stimulated with 200ng / mL Ultrapure LPS-B5 for 3 hours prior to the addition of pre-diluted compounds. 30 minutes after compound addition, 5mM ATP was added for a secondary stimulation for 45 minutes. After stimulation, plates were spun down briefly and 50μL of supernatant was taken from each well. ELISA for human IL-1b was performed on supernatants diluted 1:10 and 1:100 using a pre-coated kit. IL-1b concentrations were calculated based on pre-titrated standards and compound inhibitory IC50s were generated using the Levenberg Marquardt damped least squares method.

[0313] The examples and embodiments described herein are for illustrative purposes only, and in some embodiments, various modifications or alterations should be included within the scope of the disclosure and the appended claims.

Claims

1. Formula (I) 【Chemistry 1】 or a pharma- ceutically acceptable salt or solvate thereof, During the ceremony, X 1 is O, X 2 -N(R 5 ) - and X 3 -N(R 5 ) - and Each R 5 is hydrogen; R 1 teeth, 【Chemistry 2】 and Y 1 is O, S, or N(R 8 ); Y 2 is C(R 9 ); Y 3 is O or N(R 10 ); R 6 is —OH; each R 7 is independently selected from C 1 -C 6 alkyl, —C 1 -C 6 alkyl-CO 2 R 18 , C 1 -C 6 haloalkyl, and C 1 -C 6 heteroalkyl; R 8 is hydrogen, C 1 -C 6 alkyl, or C 1 -C 6 heteroalkyl; R 9 is hydrogen; R 10 is —OH; R 18 is hydrogen or C 1 -C 6 alkyl; n is 1 or 2; p is 0, 1, 2, 3, or 4; R 2 teeth 【Chemistry 3】 and Z is C(R 19 ); R 11 is C 1 -C 6 is alkyl, R 12 is C 1 -C 6 is alkyl, Each R 13 is halogen, C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, and C 1 -C 6 heteroalkyl; R 19 is hydrogen, q is 0 or 1; s is 1, 2, or 3; and t is 1, 2, or 3; A compound or a pharma- ceutically acceptable salt or solvate thereof.

2. R 1 but 【Chemistry 4】 2. The compound of claim 1, wherein:

3. R 1 but 【Chemistry 5】 And Y 3 N (R 10 2. The compound of claim 1, wherein:

4. Y 1 The compound of claim 1 , or a pharma- ceutically acceptable salt or solvate thereof, wherein

5. Each R 7 C 1 -C 6 2. The compound of claim 1, or a pharma- ceutically acceptable salt or solvate thereof, wherein: R is independently selected from: alkyl;

6. 2. The compound of claim 1, or a pharma- ceutically acceptable salt or solvate thereof, wherein p is 0 or 1.

7. R 1 but, 【Chemistry 6】 2. The compound of claim 1, wherein:

8. R 2 but 【Chemistry 7】 2. The compound of claim 1, wherein: s is 1 and t is 1, or a pharma- ceutically acceptable salt or solvate thereof.

9. R 2 but 【Chemistry 8】 and each R 13 But halogen, C 1 -C 6 Alkyl, and C 1 -C 6 2. The compound of claim 1, or a pharma- ceutically acceptable salt or solvate thereof, independently selected from haloalkyl.

10. 10. The compound of claim 9, or a pharma- ceutically acceptable salt or solvate thereof, wherein q is 0 or 1.

11. R 2 but, 【Chemistry 9】 2. The compound of claim 1, wherein:

12. 【Catalog 10】 【Chemistry 11】 【Chemistry 12】 2. The compound of claim 1, selected from:

13. A pharmaceutical composition comprising a compound according to any one of claims 1 to 12 or a pharma- ceutically acceptable salt or solvate thereof, and a pharma- ceutically acceptable excipient.

14. 13. Use of a compound according to any one of claims 1 to 12, or a pharma- ceutically acceptable salt or solvate thereof, in the manufacture of a medicament for treating a metabolic disease, a hepatic disease, a pulmonary disease, a central nervous system disease, a cardiovascular disease, or an inflammatory or autoimmune disease in a patient in need of such treatment.

15. 15. The use of claim 14, wherein the metabolic disease is selected from type 2 diabetes, atherosclerosis, obesity, and gout, the liver disease is selected from nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH), viral hepatitis, and cirrhosis, the lung disease is selected from asthma, chronic obstructive pulmonary disease (COPD), and idiopathic pulmonary fibrosis, the central nervous system disease is selected from Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis, and Parkinson's disease, the cardiovascular disease is atherosclerosis or stroke, and the inflammatory or autoimmune disease is selected from rheumatoid arthritis, multiple sclerosis, psoriasis, lupus, inflammatory bowel disease, Crohn's disease, and ulcerative colitis.

Citation Information

Patent Citations

  • Sulfonylureas and related compounds and uses thereof

    JP2018510207A

  • Compounds and compositions for treating conditions associated with NLRP activity

    JP2019519598A

  • Sulphonamides and compositions thereof for treating conditions associated with NLRP activity

    WO2019079119A1